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Abstract 31 
Background: Complex traumatic events associated with armed conflict, forcible displacement, 32 
childhood sexual abuse and domestic violence are increasingly prevalent. People exposed to 33 
complex traumatic events are at not only at risk of post-traumatic stress disorder (PTSD) but also 34 
other mental health comorbidities. While evidence-based psychological and pharmacological 35 
treatments are effective for single event PTSD it is not known if people who have experienced 36 
complex traumatic events can benefit and tolerate these commonly available treatments. 37 
Furthermore, it is not known which components of psychological interventions are most effective for 38 
managing PTSD in this population. We performed a systematic review and component network 39 
meta-analysis to assess the effectiveness of psychological and pharmacological interventions for 40 
managing mental health problems in people exposed to complex traumatic events. 41 
 42 
Methods and Findings: We searched CINAHL, Cochrane Central Register of Controlled Trials, 43 
EMBASE, International Pharmaceutical Abstracts, MEDLINE, Published International Literature on 44 
Traumatic Stress, PsycINFO, and Science Citation Index for randomised and non-randomised 45 
controlled trials of psychological and pharmacological treatments for PTSD symptoms n people 46 
exposed to complex traumatic events, published up to 25th October 2019. We adopted a non-47 
diagnostic approach and included studies of adults who have experienced complex trauma. Complex 48 
trauma sub-groups were: veterans; childhood sexual abuse; war-affected; refugees; and domestic 49 
violence. The primary outcome was reduction in PTSD symptoms. Secondary outcomes were 50 
depressive and anxiety symptoms, quality of life, sleep quality, and positive and negative affect. We 51 
included 116 studies, of which 50 were conducted in hospital settings, 24 were delivered in 52 
community settings, seven were delivered in military clinics for veterans or active military personnel, 53 
five were conducted in refugee camps, four used remote delivery via web based or telephone 54 
platforms, four were conducted in specialist trauma clinics, two were delivered in home settings, 55 
and two were delivered in primary care clinics; clinical setting was not reported in 17 studies. 56 
Ninety-four RCTs for a total of 6158 participants were included in meta-analyses across the primary 57 
and secondary outcomes; 19 RCTs for a total of 933 participants were included in the component 58 
network meta-analysis. The mean age of participants in the included RCTs was 42.6 ±9.3 years, and 59 
42% were male. Nine non-randomised controlled trials were included. The mean age of participants 60 
in the non-randomised controlled trials was 40.6 ±9.4 years, and 47% were male. The average length 61 
of follow-up across all included studies at post-treatment for the primary outcome was 11.5 weeks. 62 
The pair-wise meta-analysis showed that psychological interventions reduce PTSD symptoms more 63 
than inactive control (k=46; n=3389; standardised mean difference, SMD=-0.82, 95% CI: -1.02 to -64 
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0.63) and active control (k-9; n=662; SMD=-0.35, 95% CI: -0.56 to -0.14) at post-treatment, and also 65 
compared with inactive control at 6-month follow-up (k=10; n=738; SMD=-0.45, 95% CI: -0.82 to -66 
0.08). Psychological interventions reduced depressive symptoms (k=31; n=2075; SMD=-0.87, 95% CI: 67 
-1.11 to -0.63; I2=82.7%, p=0.000) and anxiety (k=15; n=1395; SMD=-1.03, 95% CI: -1.44 to -0.61; 68 
p=0.000) at post-treatment comparted with inactive control. Sleep quality was significantly 69 
improved at post-treatment by psychological interventions compared with inactive control (k=3; 70 
n=111; SMD=-1.00, 95% CI: -1.49 to-0.51; p=0.245). There were no significant differences between 71 
psychological interventions and inactive control group at post-treatment for quality of life (k=6; 72 
n=401; SMD=0.33, 95% CI: -0.01 to 0.66; p=0.021). Antipsychotic medicine (k=5; n=364; SMD=–0.45; 73 
–0.85 to –0.05; p=0.085) and Prazosin (k=3; n=110; SMD=-0.52; -1.03 to -0.02; p=0.182) were 74 
effective in reducing PTSD symptoms. Phase-based psychological interventions that included skills 75 
based strategies along with trauma-focused strategies were the most promising interventions for 76 
emotional dysregulation and interpersonal problems. Compared with pharmacological interventions 77 
we observed that psychological interventions were associated with greater reductions in PTSD and 78 
depression symptoms and improved sleep quality. Sensitivity analysis showed that psychological 79 
interventions were acceptable with lower drop out, even in studies rated at low risk of attrition bias. 80 
Trauma-focused psychological interventions were superior to non-trauma focused interventions 81 
across trauma sub-groups for PTSD symptoms, but effects among veterans and war-affected 82 
populations were significantly reduced. The network meta-analysis showed that multi-component 83 
interventions that included cognitive restructuring and imaginal exposure were the most effective 84 
for reducing PTSD symptoms (k=17; n=1077; mean difference=-37.95, 95% CI: -60.84 to -15.16). Our 85 
use of a non-diagnostic inclusion strategy may have over-looked certain complex trauma populations 86 
with severe and enduring mental comorbidities. Additionally, the relative contribution of skills-based 87 
intervention components were not feasibly evaluated in the network meta-analysis. 88 
 89 
Conclusions: In this systematic review and meta-analysis we observed that trauma-focused 90 
psychological interventions are effective for managing mental health problems and comorbidities in 91 
people exposed to complex trauma. Multi-component interventions, which can include phase-based 92 
approaches, were the most effective treatment package for managing PTSD in complex trauma. 93 
Establishing optimal ways to deliver multicomponent psychological interventions for people exposed 94 
to complex traumatic events is a research and clinical priority.  95 
 96 
 97 
 98 
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Why was the study done? 99 
 Complex traumatic events are of a multiple or prolonged nature and are increasingly 100 
prevalent owing to unprecedented levels of population displacement, armed conflict, and 101 
increased recognition of childhood sexual abuse and domestic violence. 102 
 People exposed to complex traumatic events are at not only at risk of post-traumatic stress 103 
disorder (PTSD) but also other mental health problems. 104 
 There are evidence-based psychological and pharmacological treatments for single event 105 
PTSD but it is not known if people who have suffered complex traumatic events can benefit 106 
and tolerate commonly available treatments. 107 
 To inform treatment guidelines and future research a broad evidence synthesis is needed 108 
that goes beyond existing knowledge to identify candidate interventions for mental health 109 
problems associated with complex trauma. 110 
 111 
What did the researchers do and find? 112 
 We undertook a systematic review and meta-analysis of the effectiveness and acceptability 113 
of psychological and pharmacological treatments for mental health problems in veterans, 114 
refugees, victims of childhood sexual abuse and domestic violence, and war-affected 115 
populations. 116 
 We used network meta-analysis to disentangle the relative contribution of different 117 
components of psychological treatments. 118 
 The meta-analysis showed that psychological treatments are effective for treating PTSD, 119 
anxiety, depression, and improving sleep in people with a history of complex traumatic 120 
events. 121 
 Pharmacological interventions were less effective than psychological interventions for 122 
treating PTSD symptoms and improving sleep. 123 
 Trauma-focused treatments were the most effective approaches, but these treatments 124 
tended to be less effective in veterans and war-affected populations. 125 
 Multi-component interventions that included two or more components were the most 126 
effective for treating PTSD symptoms and these approaches were promising for the 127 
management of disturbances of self-organisation. 128 
 129 
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What do these findings mean? 130 
 Existing evidence-based trauma-focused psychological treatments can be effectively used as 131 
first line therapy for PTSD and mental health comorbidities in people exposed to complex 132 
trauma. 133 
 Because phasing of treatment was categorised as a constituent part of multi-component 134 
interventions there is a case to move beyond binary distinctions of phased-based versus 135 
non-phased based interventions which has hampered progress in PTSD research. 136 
 Future studies could test the most effective means to deliver patient-centred and multi-137 
component interventions for people exposed to complex trauma, especially in those with 138 
higher levels of mental health comorbidity.  139 
  140 
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Introduction 141 
Complex trauma is an increasing threat to global mental health. Complex trauma is defined as 142 
exposure to multiple or prolonged traumatic events, typically of an interpersonal nature and from 143 
which escape is impossible or difficult. Beyond the prototypical case of childhood sexual abuse 144 
complex trauma exposure is also common among those who experience intimate partner violence 145 
and conflict. Intimate partner violence accounts for 14% of lifetime traumas and is associated with a 146 
conditional risk of post-traumatic stress disorder (PTSD) of 11.4%; war-related trauma among 147 
military personnel, civilians, and refugees accounts for a further 13.1% of lifetime trauma exposures 148 
and is associated with a conditional risk of PTSD of 3.5% [1]. 149 
The burden of mental illness among veterans and forcibly displaced people is of critical 150 
contemporary relevance. Among UK veterans PTSD prevalence has increased from 4% to 6% in the 151 
last ten years and anxiety and depression occur in 31% who held combat roles [2]. UK veterans also 152 
report high levels of pre-service adversity and PTSD severity in this population is associated with 153 
childhood adversity [3]. Even higher rates of PTSD and mental health comorbidities are reported 154 
among forcibly displaced people [4]. A record 70.8 million people were displaced at the end of 2018 155 
and the vast proportion seek refuge and asylum in high-income countries with significant 156 
implications for health service delivery and budgets [5]. 157 
Individual trauma-focused cognitive behavioural therapy (TF-CBT) and eye movement 158 
desensitisation and reprocessing (EMDR) therapy are effective for reducing clinician rated PTSD 159 
symptoms [6-8]. Pharmacological treatments are also effective for managing PTSD symptoms but to 160 
a lesser degree [9]. However, treatment adherence and recovery rates can be low [10]. There is 161 
evidence that complexity of trauma exposure is associated with greater number of different types of 162 
comorbid symptoms in addition to PTSD [11, 12], and multiple comorbidity of symptoms may 163 
contribute to poorer outcome. Indeed, high levels of complex psychiatric comorbidities may 164 
negatively affect treatment outcomes for people with PTSD [13]. 165 
Risk of drop-out and reduced treatment efficacy is of particular concern in the presence of complex 166 
PTSD (CPTSD) which has recently been recognised by ICD-11 as a new diagnosis. CPTSD includes the 167 
core symptoms of PTSD (increased anxiety and emotional arousal, avoidance and numbing, re-168 
experiencing the traumatic event) and additional symptoms associated with disturbances of self-169 
organisation (affective dysregulation, negative self-concept, and interpersonal problems) [14]. A 170 
recent meta-analysis of evidence-based therapies for PTSD found that a history of childhood trauma 171 
was associated with less beneficial outcomes for all six symptom domains described in CPTSD [15]. 172 
These results suggest the importance of exploring the impact of other types of complex trauma 173 
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experiences on symptom outcomes. Furthermore, we still do not know which treatment 174 
components are most effective and acceptable for people with PTSD following complex trauma 175 
histories. 176 
Because of the narrow analytical focus and limitations of the current evidence base we conducted a 177 
systematic review to identify and integrate all direct and indirect comparisons of psychological and 178 
pharmacological treatments versus usual care and active controls in treating mental health problems 179 
in people with a history of complex traumatic events. We present post-treatment and short-term 180 
effectiveness and acceptability results using pair-wise meta-analysis and assessed the relative 181 
efficacy of different components of psychological interventions using component network meta-182 
analysis.  183 
 184 
Methods 185 
The protocol for this study was registered on PROSPERO (CRD42017055523) and can be found at: 186 
dx.doi.org/10.17504/protocols.io.bdbni2me. We followed the PRISMA extension statement for 187 
network meta-analyses (S1 Text) [16].  188 
Study design and participants 189 
We included randomised controlled trials (RCTs) and non-randomised controlled trials of 190 
psychological and/or pharmacological interventions for adults with a history of complex traumatic 191 
events. Following independent peer review during the development of the protocol it was agreed 192 
with the study steering committee that non-randomised controlled studies would be included to 193 
capture data on emerging treatments and treatments tested in more pragmatic settings. Complex 194 
traumatic events were defined as extreme and prolonged or repetitive in nature and experienced as 195 
extremely threatening or horrific and difficult or impossible to escape from [17]. Inclusion was based 196 
on the type of exposure rather than the ICD-11 diagnostic category of CPTSD. Candidate exposures 197 
included (but were not limited to) childhood physical and/or sexual abuse, domestic violence, 198 
forcible displacement, torture, on-going armed conflict and combat, and human trafficking. 199 
 200 
Interventions and comparators 201 
First or second line psychological therapies aimed at improving PTSD symptoms and mental health 202 
comorbidities either delivered to individuals or in a group were included. As per our protocol and in-203 
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keeping with the classification used by the National Institute for Health and Care Excellence (NICE)[6] 204 
interventions considered were: a) TF-CBT that included one or more of exposure, cognitive therapy, 205 
stress management; b) EMDR; c) other psychological treatments used to treat trauma survivors but 206 
use predominately non-CBT techniques such as supportive therapy and non-directive counselling, 207 
inter personal psychotherapy (IPT), hypnotherapy, mindfulness and compassion focused therapies, 208 
acceptance and commitment therapies, accelerated resolution, and sensorimotor therapies. We also 209 
included the following pharmacological interventions: anti-depressants (SSRIs; tricyclics and 210 
monoamine oxidase inhibitors), antipsychotics (quetiapine, aripiprazole, risperidone, olanzapine), 211 
hypnotics and anxiolytics (Z-drugs; benzodiazepines; promethazine), alpha blocker and anti-212 
hypertensive (Prazosin), and anticonvulsants (lamotrigine, topiramate, valproate).  213 
Comparators for psychological interventions were: waitlist; treatment as usual (defined as non-214 
experimental active treatments that conform to best and/or clinical guideline recommended care 215 
ordinarily made available to patients); no intervention; symptom monitoring; repeated assessment 216 
or other minimal attention control group akin to psychological placebo; and alternative 217 
psychological treatment. Comparators for pharmacological interventions were: placebo; other 218 
medication; no intervention; and psychological therapy.  219 
Comparisons of two or more active interventions were included. Differences in comparators were 220 
taken into account during data summary and analyses. Network meta-analyses were conducted to 221 
provide comparisons of all interventions within a connected network (including comparisons of 222 
active interventions not originally evaluated in included trials). 223 
 224 
Outcomes 225 
The primary outcome was reduction in severity of PTSD symptoms as measured using a validated 226 
and standardised clinician rated scale. Secondary outcomes were: reductions in symptoms of 227 
disturbances of self-organisation (affect dysregulation; negative self-concept; disturbances in 228 
relationships); reduction in symptoms of depression and anxiety, dissociation, functional somatic 229 
syndromes; acceptability(attrition); adverse events and harms from trial data (e.g. worsening of 230 
traumatic stress symptoms); suicidal ideation, attempts, and completion; and quality of life 231 
measured by validated clinician-rated scales. Study outcomes were measured at post-treatment 232 
and/or at the follow-up point defined by the study. 233 
 234 
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Search strategy and selection criteria 235 
Literature searches were initially conducted in April 2017 in these databases: CINAHL, Cochrane 236 
Central Register of Controlled Trials (CENTRAL), Embase, International Pharmaceutical Abstracts, 237 
MEDLINE, Published International Literature on Traumatic Stress (PILOTS), PsycINFO, and Science 238 
Citation Index. The search results for each database were downloaded, imported into EndNote 239 
bibliographic software and deduplicated. A full update search was conducted in August 2018. Finally, 240 
update searches using the MEDLINE and PsycINFO databases were carried out in October 2019. 241 
Details of search dates, database interfaces and the full search strategies used are available from the 242 
corresponding author. We did not restrict on language and translated studies where feasible, but we 243 
did not search Chinese databases or translate this language. A sample MEDLINE search is shown in 244 
S2 Text. 245 
Studies were eligible if they met these criteria: a) peer reviewed original articles; b) RCTs and non-246 
randomised controlled trials; c) measured either the primary or one of the candidate secondary 247 
outcomes. The exclusion criteria were: a) reviews/non-original data; b) dissertations or conference 248 
presentations; c) complementary and alternative therapeutic interventions that were not 249 
underpinned by a recognisable psychological focus (i.e. yoga; dance, music, art). To ensure that the 250 
inclusion criteria were consistently applied, a 10% sample of records was first double screened based 251 
on title and abstract by pairs of researchers. Consensus meetings with the rest of the research team 252 
were held at regular intervals to resolve unclear decisions at the title and abstract screening phase. 253 
Full text records were similarly screened with consensus meetings used to resolve disagreements. 254 
 255 
Data extraction 256 
Data extraction was piloted on a small sample of studies by three researchers independently. Both 257 
RCTs and non-randomised controlled studies were extracted using the same template, and managed 258 
in separate Excel spreadsheets. After consensus checking, included records were split between three 259 
reviewers to singly extract owing to the volume of evidence. Uncertainties were resolved by 260 
consultation between reviewers tasked with data extraction or by deferring to the wider review 261 
team. Extracted data across domains related to study and participant characteristics and outcomes 262 
were compiled in a spreadsheet. Where presented, intention-to-treat data were extracted instead of 263 
complete cases.  264 
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Where an included study was published across multiple manuscripts we used the primary 265 
publication as the main source of information. New and follow-up data were taken from subsequent 266 
publications but the unit of allocation remained the study rather than numbers of publications. 267 
 268 
Risk of bias 269 
Risk of bias for RCTs was assessed with the Cochrane Risk of Bias tool [18]. This tool assessed each 270 
study against domains known to be associated with bias in randomised controlled trials: selection, 271 
performance, detection, attrition, reporting, and other bias (which was applied based on the specific 272 
context. Each study was assessed as being at either ‘low’, ‘unclear’ or ‘high’ risk of bias across each 273 
of these domains. Attrition bias was used as an independent variable in the sensitivity analysis; this 274 
domain was checked by a further reviewer after all the original appraisals had been made. Overall, 275 
RCTs were classified as having low risk of bias if none of the domains were rated as high risk of bias 276 
and three or less were rated as unclear risk; moderate if one was rated as high risk of bias or none 277 
was rated as high risk of bias but four or more were rated as unclear risk. All other cases were 278 
assumed to be at high risk of bias [19].  279 
Studies of non-randomised controlled trials were assessed for risk of bias using a modified version of 280 
the NICE (2012) quality appraisal checklist [20]. This checklist was originally developed based on the 281 
‘Graphical Appraisal Tool for Epidemiological studies’ (GATE) tool, and includes domains of 282 
population bias, allocation, outcomes and analyses, as well as summary judgements for internal and 283 
external validity [21].  284 
 285 
Statistical analysis 286 
Random-effects pair-wise meta-analyses were conducted using Stata 15 [22]. Control conditions 287 
were grouped into two categories: control (which included waitlist, usual care, no treatment, or 288 
other control with no or minimal therapeutic input) and active control (attention controls or 289 
treatment as usual with non-systematic psychological intervention input). Where multiple 290 
intervention groups were included in the study we analysed the data in the following way: a) if one 291 
of the groups did not meet criteria for our review we did not combine across groups but used data 292 
from the group that met our review criteria; b) where studies included two intervention groups that 293 
met criteria for the same intervention classification we combined them together. For example, if a 294 
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study included a prolonged exposure group and a cognitive processing therapy group we combined 295 
them together into one group for the trauma-focused CBT analyses. 296 
 297 
Most outcomes were continuous. Where all studies used the same scale we calculated mean 298 
differences (MD) and their 95% confidence interval. Where studies used different scales to measure 299 
a particular outcome we calculated standardized mean differences (SMD) and their 95% confidence 300 
interval. In keeping with established cut-offs of effect in behavioural medicine, SMDs of 0.56 to 1.2 301 
were categorised as large; effect sizes of 0.33 to 0.55 as moderate, and effect sizes ≤0.32 as small 302 
[23]. For dichotomous outcomes, such as attrition, we calculated odds ratios (OR) and their 95% 303 
confidence interval. Heterogeneity assessment was based on visual inspection of forest plots and the 304 
I2 statistic [24] A Q-value (approximating Χ2 distribution) of p<0.1 indicated statistically significant 305 
heterogeneity. Statistical heterogeneity was explored using subgroup analyses and components 306 
network meta-analyses. 307 
 308 
Given the substantial and inherent heterogeneity expected from our broad research questions we 309 
conducted a range of subgroup analyses. Firstly, we conducted meta-analyses including all 310 
psychological interventions vs inactive controls or active controls in all populations. Secondly, we 311 
subgrouped these meta-analyses of all psychological interventions into the following populations 312 
based on descriptions in the study and through discussion with clinical experts: veterans, people 313 
who had experienced childhood sexual abuse, refugees, people who had experienced domestic 314 
violence, and war affected civilians. Thirdly, we subgrouped the data according to intervention 315 
categories commonly reported in the literature based on reporting from the original papers and 316 
discussion with clinical experts: TF-CBT, EMDR, non-trauma focused CBT, mindfulness, dialectical 317 
behaviour therapy (DBT) and interpersonal psychotherapy (IPT).  318 
 319 
We sought to further explore the impact of different combinations of psychological intervention 320 
components using network meta-analyses. We used a Bayesian approach as this allows greater 321 
flexibility in fitting more complex models and aids exploration of heterogeneity. Given the greater 322 
complexity of the network meta-analysis models we simplified the analyses by focusing on mean 323 
differences for the Clinician-Administered PTSD Scale in all populations for this outcome.  324 
 325 
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We fitted models using WinBUGS 1.4.3 based on the components network meta-analyses (NMA) 326 
approach proposed by Welton et al [25] and an adaptation of the WinBUGS code reported in 327 
Freeman et al [26]. The advantages of this approach is that all intervention components can be 328 
included in the meta-analyses as long as they form a connected network. An important assumption 329 
of the network meta-analysis is consistency between direct (i.e. where trials have specifically 330 
compared two or more interventions) and indirect (i.e. data derived from the network where trials 331 
have not directly compared interventions) evidence. To assess the validity of this assumption we 332 
examined participant and study characteristics and sought input from topic experts. Based on this 333 
assessment we judged the data similar enough to combine in the network meta-analysis. However, 334 
as is common in most network meta-analyses, there was insufficient data to statistically test this 335 
assumption. 336 
 337 
All models used a normal likelihood for continuous outcomes and vague priors for treatment effect 338 
and between trial standard deviation. Convergence was assessed based on visual assessment of 339 
trace plots, the Brooks-Gelman-Rubin statistic, and autocorrelation plots using three Markov Chain 340 
Monte Carlo chains. All models were judged to have reached convergence after 50,000 iterations. 341 
These iterations were then discarded and all results were based on a further 50,000 iterations.  342 
 343 
Goodness of fit to the observed data was assessed using total residual deviance and the deviance 344 
information criterion (DIC). Total residual deviance approximately equal to the number of data 345 
points was considered to indicate acceptable fit [27]. Greater than five points on the DIC was 346 
considered a substantial difference in goodness of fit between models [28]. 347 
 348 
We compared four models: a) model 1 included the intervention categories used in the pair-wise 349 
meta-analyses (TF-CBT, EMDR, non-trauma focused CBT, mindfulness, and IPT) compared with either 350 
control or active control; b) model 2 included all intervention components included in the 351 
intervention categories from model 1 (support, psychoeducation, relaxation, cognitive restructuring, 352 
in vivo exposure, imaginal exposure, virtual reality exposure, mindfulness, phased-based). In 353 
addition to these it was also assumed that all active treatments and attention controls included a 354 
placebo component. We also took into account the effect of control group (waitlist vs active 355 
control). Each component had a separate effect and assumed the total effect of the intervention was 356 
a sum of these separate effects; c) model 3 included all intervention components in Model 2 plus all 357 
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available pairs of components. Ten pairs of intervention components were reported in two or more 358 
included studies: support + psychoeducation, psychoeducation + relaxation, psychoeducation + 359 
cognitive restructuring, psychoeducation + imaginal exposure, relaxation + mindfulness, relaxation + 360 
cognitive restructuring, relaxation + imaginal exposure, mindfulness + cognitive restructuring, 361 
cognitive restructuring + in vivo exposure, cognitive restructuring + imaginal exposure and were 362 
therefore included in the analyses. This model allowed for interactions between pairs of 363 
interventions above or below what would be expected from the sum of their components; d) model 364 
4 included all possible combinations of intervention components. 365 
For the attrition outcome, we were concerned that any differences between interventions and 366 
control may be confounded by study design characteristics. Therefore, we conducted sensitivity 367 
analyses on attrition outcomes, including only studies with low risk of attrition bias and compared 368 
these findings with all included studies. 369 
 370 
Results 371 
Characteristics of the included studies 372 
11,845 non-duplicate references were identified by the search (last update October 25, 2019), and 373 
518 full text articles were assessed for eligibility (Fig 1). We included 116 studies (115 papers) in the 374 
systematic review. Of these 50 were conducted in hospital settings [29-78], 24 were delivered in a 375 
community setting [79-102], seven were delivered in military clinics for veterans or active military 376 
personnel [103-109], five were conducted in refugee camps [110-114], four used remote delivery via 377 
web based or telephone platforms [115-118], four were conducted in specialist trauma clinics [119-378 
122], two were delivered in home settings [123, 124], and two were delivered in primary care clinics 379 
[125, 126]; clinical setting was not reported in 17 studies [127-143].  380 
 381 
Figure 1 PRISMA flow diagram 382 
 383 
Ninety-four (n=6158 participants) RCTs were included in meta-analyses across the primary and 384 
secondary outcomes. Nineteen RCTs (n=933 participants) of psychological interventions that 385 
measured the primary outcome with CAPS were included in the network meta-analysis [29, 36, 44, 386 
59, 68, 84, 88, 91-93, 100, 106, 107, 109, 116, 120, 123]. The complex trauma sub-groups of the 387 
included studies were categorised as follows: post-combat deployment veterans (55 studies) [32-35, 388 
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37, 39-41, 43-48, 50-54, 56, 58, 60-63, 66-71, 73, 74, 76, 77, 82, 90, 100, 103, 104, 106-108, 115, 116, 389 
121, 123, 124, 127, 128, 132, 133, 136, 143]; war-related (16 studies; 15 papers) [30, 79, 80, 86, 96, 390 
101, 102, 109, 117, 118, 122, 125, 126, 134, 139]; childhood sexual abuse (17 studies) [36, 38, 49, 55, 391 
57, 59, 72, 84, 91, 95, 97, 98, 129, 135, 141, 142]; refugees (19 studies) [29, 64, 65, 75, 81, 83, 87-89, 392 
94, 99, 110-114, 119, 120, 140]; domestic violence (5 studies) [31, 92, 93, 131, 137]; and mixed 393 
presentation (4 studies) [78, 85, 105, 130]. The mean age of participants in the included RCTs was 394 
42.6 ±9.3 years, and 42% were male (S1 Table).  395 
Across the 51 (n=4018 participants) RCTs of psychological interventions included in the meta-396 
analyses of the primary outcome there were 27 comparisons of TF-CBT, nine comparisons of EMDR, 397 
two comparisons of IPT, three comparisons of mindfulness, three comparisons of non-trauma 398 
focused CBT, and seven comparisons of dialectical behaviour therapy. TF-CBT was delivered over a 399 
mean of 10.3 weeks with an average of 1.2 sessions a week lasting on average 59.4 minutes. Non-400 
trauma focused CBT was delivered over a mean of 12 weeks with an average of 1.5 sessions a week 401 
for an average of 68.6 minutes. The duration of EMDR was shorter, delivered over a mean of 5.2 402 
weeks, with an average of 1.1 sessions a week for an average of 61 minutes each. Mindfulness was 403 
delivered over a mean of 6.6. weeks, with an average of 1.1 sessions a week lasting an average of 404 
121.6 minutes per session. There was insufficient data to report mean duration, frequency and 405 
length of sessions for IPT and dialectical behavioural therapy. 406 
Sixteen (n=1233 participants) of 19 RCTs contributed data to meta-analyses of pharmacological 407 
interventions versus placebo. These studies included six comparisons of antidepressants (of these, 408 
four comparisons were of SSRIs), five comparisons of anti-psychotics, two comparisons of anti-409 
convulsants, and three comparisons of Prazosin. Of those studies that compared SSRIs with a 410 
placebo control there was only sufficient data from trials that tested sertraline and paroxetine to 411 
report mean duration, frequency and dosing. Sertraline was prescribed for a mean of 9.5 weeks, to 412 
be taken daily, with a mean dose of 50mg. Paroxetine was prescribed for a mean of 8.6 weeks, to be 413 
taken daily, with a mean dose of 30mg.  414 
 415 
Nine non-randomised controlled trials were included and of these six reported data for the primary 416 
outcome [52, 57, 66, 95, 96, 132-134, 138]. The mean age of participants in the non-randomised 417 
controlled trials was 40.6 ±9.4 years, and 47% were male. Effect sizes were calculated for four of 418 
these studies (representing five interventions) as they used inactive control comparators. All 419 
comparisons were of TF-CBT. 420 
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Of the 22 RCTs not included in the meta-analyses five studies compared psychological interventions 421 
in veterans. Of these two studies compared TF-CBT with present centred therapy and one study 422 
compared mindfulness with present centred therapy [67, 108]. Additionally one study compared TF-423 
CBT with exposure alone and another study did not include extractable data [103]. Two RCTs were 424 
identified that compared combined psychological and pharmacological interventions but included 425 
different classes of drugs. Of these one study was in veterans and compared phenelzine and 426 
psychotherapy with imipramine and psychotherapy and with psychotherapy alone [90]. A further 427 
study was in a mixed population and compared tianeptine and group therapy with fluoxetine and 428 
group therapy [130]. Three RCTs in veterans that compared pharmacological interventions were not 429 
included in the meta-analyses. Of these one study compared rivastigmine augmented therapy with 430 
placebo, but there were no other comparable interventions to combine these data with [127]. Two 431 
other studies were head-to-head comparisons of paroxetine with amitriptyline [35] and of 432 
mirtazapine with sertraline [37]. 433 
Three RCTs in refugees were not meta-analysed. One study compared TF-CBT, supportive 434 
counselling, and psychoeducation and did not include a comparison with a control group [112]. 435 
Another study compared TF-CBT with an exposure only intervention [65], and one comparison of TF-436 
CBT with treatment as usual did not include extractable data [75]. Among RCTs that assessed anxiety 437 
in refugees three studies compared combined psychological and pharmacological interventions but 438 
no meta-analyses were possible [64, 81, 99]. Additionally one RCT in refugees compared paroxetine 439 
with sertraline, but this was the only study in this sub-group that used this comparison and no meta-440 
analysis was possible [140].  441 
In RCTs among war-affected populations one study did not report outcomes that were similar 442 
enough with other studies [30], and another study used a head-to-head design that compared TF-443 
CBT with psychoeducation [79].  444 
Four RCTs in populations with a history of childhood sexual abuse were not included in meta-445 
analyses. One study attempted to deconstruct how skills training drove the effectiveness and 446 
interacted with counselling and exposure respectively and did not offer opportunities to formally 447 
compare outcomes with an inactive or active control group [84]. A head-to-head design was used by 448 
one study to compare analytic group psychotherapy with systemic group psychotherapy [55], while 449 
another study combined data from TF-CBT and present centred therapy making it difficult to extract 450 
relevant data [38]. A further study that compared TF-CBT with a minimal attention control group did 451 
not include data that could be compared with other studies [135].  452 
 453 
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Risk of bias assessment 454 
Forty, 25 and 42 RCTs were categorised as being of low, moderate, and high risk of bias respectively. 455 
For RCTs the risk of bias from random sequence generation was low in 35 (32%) studies; and low for 456 
allocation concealment in 12 (11%). Two, four and three non-RCTs were categorised as being of low, 457 
moderate and high risk of bias. For non-RCTs risk of bias associated with selection bias was low in 458 
only two studies (11%). A breakdown of risk of bias by individual domains for RCTs is shown in the in 459 
the Table in S2 Table and for non-randomised controlled trials in the Table in S3 Table.  460 
 461 
Acceptability 462 
The acceptability sensitivity analysis showed that participants across all populations allocated to 463 
psychological interventions in studies judged to be at low risk of attrition bias were still less likely to 464 
drop out compared with controls (odds ratio= 0.39; 0.21 to 0.73) than in all studies (OR=0.56; 0.40 to 465 
0.80).  466 
 467 
Primary outcome: PTSD symptoms 468 
Effectiveness at post-treatment 469 
The pair-wise meta-analysis results for primary and secondary outcomes across all populations at 470 
post-treatment and follow-up versus control are shown in the Table in S4 Table. Across 46 trials in all 471 
populations, psychological treatments were effective at post-treatment in reducing PTSD symptoms 472 
in people with a history of complex traumatic events (Fig 2). Across all populations TF-CBT, IPT, and 473 
EMDR were associated with large treatment effects in favour of the interventions at post-treatment 474 
when compared with control (Fig 3). The 95% CIs for IPT were large, suggesting substantial 475 
imprecision. Smaller but still significant effects were observed at post-treatment when TF-CBT was 476 
compared with an active control (k=3; n=447; SMD=-0.30; -0.50 to -0.10; I2=13.2%, p=0.32). There 477 
was also evidence from six trials that phase-based interventions that included components to 478 
improve daily functioning as well as trauma-focused therapy were effective at reducing PTSD 479 
symptoms at post-treatment compared with control. Treatment effects associated with non-trauma 480 
focused interventions were small and not significant. 481 
 482 
Figure 2 Any psychological treatment for PTSD symptoms versus control at post-treatment across all 483 
populations 484 
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ES: effect size. The size of the grey box reflects how much weight each study received in the meta-485 
analysis (i.e. the larger the box the more this study contributed to the pooled effect represented by 486 
the blue diamond). Black bars represent the 95% confidence interval for the effect size in each study  487 
 488 
Figure 3 Psychological treatments for PTSD symptoms by intervention category versus control at 489 
post-treatment across all populations 490 
CBT: cognitive behavioural therapy, EMDR: eye movement desensitisation and reprocessing therapy, 491 
ES: effect size, IPT: interpersonal therapy. The size of the grey box reflects how much weight each 492 
study received in the meta-analysis (i.e. the larger the box the more this study contributed to the 493 
pooled effect represented by the blue diamond). Black bars represent the 95% confidence interval 494 
for the effect size in each study 495 
 496 
Eight trials compared pharmacological interventions with placebo for reducing PTSD symptoms. 497 
Overall, antipsychotic medicine (k=5; n=364; SMD=–0.45; –0.85 to –0.05; I2=51.2%, p=0.085) (Fig 4) 498 
and Prazosin (k=3; n=110; SMD=-0.52; -1.03 to -0.02; I2=41.4%, p=0.182) (Fig 5) were effective in 499 
reducing PTSD symptoms. 500 
 501 
Figure 4 Antipsychotics versus placebo for PTSD symptoms at post-treatment 502 
SMD: standardised mean difference. The size of the grey box reflects how much weight each study 503 
received in the meta-analysis (i.e. the larger the box the more this study contributed to the pooled 504 
effect represented by the blue diamond). Black bars represent the 95% confidence interval for the 505 
effect size in each study 506 
Figure 5 Prazosin versus placebo for PTSD symptoms at post-treatment 507 
SMD: standardised mean difference. The size of the grey box reflects how much weight each study 508 
received in the meta-analysis (i.e. the larger the box the more this study contributed to the pooled 509 
effect represented by the blue diamond). Black bars represent the 95% confidence interval for the 510 
effect size in each study 511 
 512 
Effectiveness at six-month follow-up 513 
All psychological treatments were effective compared with control at 6-month follow-up (k=10; 514 
n=738; SMD=-0.45; -0.82 to -0.08; I2=79.4%; p<.001). There was further evidence from four trials 515 
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that TF-CBT conferred most benefit, with large treatment effects reported at 6-month follow-up 516 
(k=4; n=206; SMD=-0.64; -1.10 to-0.18; I2; p=0.14).  517 
 518 
Sub-group analyses 519 
The pair-wise meta-analyses results for the primary outcome by sub-group are presented in the 520 
Table in S5 Table. It was not possible to conduct meta-analyses for pharmacological interventions by 521 
population as all but one of these studies were conducted in veterans. 522 
 523 
Veterans 524 
Among veterans, evidence from 15 trials showed that psychological interventions compared with 525 
control were effective at post-treatment for reducing PTSD symptoms, but the size of the treatment 526 
effect was smaller than in the pooled analysis across all populations. Additionally, unlike the pooled 527 
analysis across all populations these positive effects were not maintained at 6-month follow-up. 528 
However, when compared with an active control in six trials psychological interventions were 529 
associated with a moderate and significant effect size at post-treatment (k=6; n=260; SMD=–0.40; –530 
0.77 to -0.02; I2=48.7%, p=0.08). Results by intervention category are shown in Figure 6. In seven 531 
trials and four trials respectively TF-CBT and EMDR were associated with the largest treatment effect 532 
at post-treatment compared with control, but the effect size was reduced by a third when compared 533 
with the pooled analysis across all populations. Treatment effects associated with mindfulness 534 
favoured the intervention at post-treatment and 6-month follow-up compared with control but the 535 
difference was not significant in either comparison. 536 
 537 
Figure 6 Psychological treatments for PTSD symptoms by intervention category versus control at 538 
post-treatment in veterans 539 
CBT: cognitive behavioural therapy, EMDR: eye movement desensitisation and reprocessing therapy, 540 
SMD: standardised mean difference. The size of the grey box reflects how much weight each study 541 
received in the meta-analysis (i.e. the larger the box the more this study contributed to the pooled 542 
effect represented by the blue diamond). Black bars represent the 95% confidence interval for the 543 
effect size in each study 544 
 545 
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Refugees  546 
Psychological interventions are effective for reducing PTSD symptoms in refugee populations in 547 
seven trials at post-treatment and in three trials at 6-month follow up compared with control. 548 
Evidence from two trials showed that TF-CBT conferred the most benefit at post-treatment 549 
compared with control, but the large effects were not maintained in two trials at 6-month follow-up. 550 
EMDR was also associated with large and significant treatment effects in three trials at post-551 
treatment when compared with control (Fig 7).  552 
 553 
Figure 7 Psychological treatments for PTSD symptoms by intervention category versus control at 554 
post-treatment in refugee populations 555 
CBT: cognitive behavioural therapy, EMDR: eye movement desensitisation and reprocessing therapy, 556 
SMD: standardised mean difference. The size of the grey box reflects how much weight each study 557 
received in the meta-analysis (i.e. the larger the box the more this study contributed to the pooled 558 
effect represented by the blue diamond). Black bars represent the 95% confidence interval for the 559 
effect size in each study 560 
 561 
Non-trauma-focused CBT was investigated in one non-randomised controlled trial in a refugee 562 
population and showed a large and significant effect favouring group intervention for reducing PTSD 563 
symptoms (k=1; n=43; SMD=–2.54, –3.21 to –1.88). 564 
 565 
Childhood sexual abuse 566 
Across 10 trials psychological interventions were effective in reducing PTSD symptoms in childhood 567 
sexual abuse populations when compared with control at post-treatment, but the difference was not 568 
significant in three trials that evaluated outcomes at 6-month follow-up. When broken down by 569 
treatment type only TF-CBT was associated positive and significant effects in three trials that 570 
compared outcomes at post-treatment with control (k=3; n=153; SMD=-1.22; -2.40 to -0.05; 571 
I2=90.3%, p=0.000), but the wide 95% CIs suggest significant imprecision in this estimate.  572 
Evidence from non-randomised controlled trials revealed a similar pattern. One study investigated 573 
‘victim to survivor’ group TF-CBT therapy and treatment effects were large and favoured the 574 
intervention at post-treatment (k=1; n=45; SMD=–1.01; –1.53 to –0.48). Another study examined a 575 
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multicomponent trauma-focused intervention delivered in a group format; a small reduction in PTSD 576 
symptoms was found, but this was not significant (k=1; n=63; SMD=–0.18; –0.62 to 0.26). 577 
 578 
War-related 579 
Evidence from six trials shows that TF-CBT is effective compared with control at post-treatment in 580 
reducing PTSD symptoms in populations affected by war. The size of the treatment effect was 581 
approximately half that observed in the comparable analysis that pooled data across all populations 582 
(Fig 8). Trauma-focused approaches were investigated in one non-randomised controlled trial which 583 
showed large treatment effects in favour of the intervention at post-treatment compared with 584 
control (k=1; n=115; SMD=–1.22; –1.75 to –0.69).  585 
 586 
Figure 8 TF-CBT for PTSD symptoms versus control at post-treatment in war-affected populations 587 
CBT: cognitive behavioural therapy, ES: effect size. The size of the grey box reflects how much weight 588 
each study received in the meta-analysis (i.e. the larger the box the more this study contributed to 589 
the pooled effect represented by the blue diamond). Black bars represent the 95% confidence 590 
interval for the effect size in each study 591 
 592 
Domestic violence 593 
TF-CBT was the most effective intervention for reducing PTSD symptoms in people exposed to 594 
domestic violence, with large and significant treatment effects observed across two trials (k=2; 595 
n=117; SMD=-2.92; -3.45 to -2.39; I2=0%, p=0.970). 596 
 597 
Secondary outcomes 598 
The pair-wise meta-analyses results for the secondary outcomes by sub-group are presented in S5 599 
Table. Only outcomes that were meta-analysed are reported.  600 
Disturbances of self-organisation symptoms 601 
Evidence from seven trials showed that treatment effects favoured psychological interventions for 602 
reducing symptoms of emotional dysregulation compared with control at post-treatment and 6-603 
month follow-up, but the differences were not significant. Evidence from two trials showed that 604 
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phase-based interventions were associated with large treatment effects in favour of reducing inter-605 
personal problems, but the difference was not significant. Across five trials negative self-concept 606 
was significantly improved by any psychological intervention at post-treatment compared with 607 
control (k=5; n=215; SMD=1.81; 0.73 to 2.89; I2=90%, p=0.000). TF-CBT was associated with large 608 
treatment effects at post-treatment compared with control in favour of improving negative self-609 
concept (k=3; n=145; SMD=2.22; 0.75 to 3.70; I2=90.4%, p=0.000), but the wide 95% CIs suggest this 610 
estimate is potentially imprecise. No studies evaluated the effect of pharmacological therapies for 611 
these outcomes.  612 
 613 
Depression 614 
Across all populations, evidence from 31 and 6 trials respectively showed psychological interventions 615 
are effective for reducing depressive symptoms at post-treatment and six-month follow-up when 616 
compared with control. Smaller positive effects were seen across five trials that compared 617 
psychological interventions at post-treatment with an active control, but the difference was not 618 
significant (k=5; n=473; SMD=-0.38; -0.76 to 0.01; I2=70.5%, p=0.009). TF-CBT was associated with 619 
the most consistently large and significant treatment effects in favour of reducing depressive 620 
symptoms at post-treatment and 6-month follow-up compared with control; in two trials TF-CBT was 621 
also effective at post-treatment when compared with an active control (k=2; n=346; SMD=-0.60; -622 
1.06 to -0.14; I2=77.7%, p=0.03). In seven trials, EMDR was similarly associated with large and 623 
significant treatment effects for reducing depressive symptoms across all populations when 624 
compared with control at post-treatment; smaller effects were observed in two trials that compared 625 
EMDR with an active control but the difference was not significant (k=2; n=72; SMD=-0.32; -1.23 to 626 
0.59; I2=47.8%, p=0.17). Large and significant effects were observed in two trials that compared IPT 627 
with control at post-treatment across all populations. Similarly, evidence from four trials showed 628 
that phase-based interventions were associated with large and significant treatment effects at post-629 
treatment when compared with control. Mindfulness was another non-trauma based intervention 630 
that proved moderately effective for reducing depressive symptoms across three trials at post-631 
treatment and two trials at 6-month follow-up. 632 
When broken down by trauma exposure evidence from three trials showed that TF-CBT is the most 633 
effective trauma-focused intervention for reducing depressive symptoms among veterans, war-634 
affected populations, childhood sexual abuse, refugees and domestic violence. The size of the 635 
treatment effect among veterans and war-affected populations was attenuated compared with the 636 
pooled analysis across all populations at post-treatment compared with control. Mindfulness was 637 
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shown to be moderately effective among veterans at post-treatment compared with control, but 638 
this difference was not significant at 6-month follow-up.  639 
 640 
Anxiety 641 
Across all populations psychological interventions were shown to be effective in 15 trials for 642 
reducing anxiety symptoms at post-treatment compared with control; two trials contributed 643 
evidence that showed that psychological interventions were moderately effective when compared 644 
with an active control (k=2; n=346; SMD=-0.44; -0.73 to -0.15; I2=46.4%, p=0.17). For all trauma 645 
types, large and significant treatment effects were observed when TF-CBT and EMDR were 646 
compared with control in eight and four trials respectively. Among veterans TF-CBT (k=3; n=112; 647 
SMD=-1.02; -1.72 to -0.32; I2=51%; p=0.130) and EMDR (k=2; n=44; SMD=-0.91; -2.28 to -0.47; 648 
I2=77.7%; p=0.034 ) were associated with the largest treatment effects for reducing anxiety 649 
symptoms when compared with control at post-treatment. TF-CBT was also the most effective 650 
intervention for reducing anxiety symptoms among war-affected populations when compared with 651 
control at post-treatment in six trials.  652 
 653 
Quality of life 654 
For all trauma types, small but non-significant improvements in quality of life were observed in six 655 
trials that compared all different psychological interventions (k=6; n=406; SMD-0.33, 95% CIL -0.01 656 
to 0.66; I2=57.3%; p=0.021) and four trials that compared TF-CBT with control at post-treatment 657 
(k=4; n=260; SM= 0.23, 95% CI: -0.33 to 0.79; I2=73.9%; p=0.009). 658 
 659 
Sleep quality 660 
Across all trauma types, sleep quality was significantly improved in analyses of three trials of 661 
psychological interventions and two trials of TF-CBT at post-treatment compared with control. 662 
Prazosin was the only pharmacological intervention with sufficient data to conduct meta-analysis. In 663 
three trials Prazosin was effective compared with placebo for improving sleep quality (k=3; n=109; 664 
SMD=-0.73;-1.12 to -0.34; I2=0%, p=0.486). 665 
 666 
Positive and negative affect 667 
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Evidence from three trials showed that antipsychotic medication (all risperidone) was not effective 668 
at post-treatment in improving negative (k=2; n=284; SMD=0.54, 95% CI: -0.14 to 1.22; I2=0%; 669 
p=0.66)and positive affect (k=3; n=329); SMD= 1.75, 95% CI: -4.05 to 0.54; I2=76.9%; p=0.01) or 670 
general psychopathology symptoms (k=2; n=284; SMD= 0.04, 95% CI: -2.08 to 2.16; I2=0%; p=0.43) in 671 
people with complex trauma. 672 
 673 
Component network meta-analysis 674 
We further explored the treatment effects of different psychological components of the included 675 
composite complex interventions by using component network meta-analysis. Model 2 had the 676 
lowest DIC (262.7, SD=8.6). However model 3 had a comparable DIC and a substantially lower 677 
between-study standard deviation (DIC=265.5, SD=6.0), suggesting heterogeneity was better 678 
accounted for. The total residual deviance was also lower in model 3, suggesting a better fit between 679 
the model and data. Given that the difference in DIC was less than three points, we selected model 3 680 
for further analyses. 681 
Figure 9 shows the network plot of combinations of treatment components for the primary outcome 682 
across the 17 studies included in the network [29, 36, 44, 59, 68, 84, 88, 91-93, 100, 106, 107, 109, 683 
116, 120, 123]. Mean differences for the primary outcome by intervention component are shown in 684 
the Table in S6 Table. Interventions that took a multicomponent approach were more effective than 685 
those that did not for reducing PTSD symptoms (k=17; n=1077; MD=-37.95; -60.84, -15.16). All these 686 
studies included cognitive restructuring and imaginal exposure. There was insufficient data to 687 
explore interactions between multicomponent approaches and these intervention components.  688 
 689 
Figure 9 Network diagram for all combinations of components extracted from included studies (edge 690 
thickness weighted by inverse variance) 691 
AC – active control, C – Cognitive restructuring, IE – Imaginal exposure, IV – In vivo exposure, M – 692 
Mindfulness, MU – Multidimensional, PE – Psychoeducation, R – Relaxation, S – support, VR – Virtual 693 
reality exposure, WL – waitlist 694 
 695 
Discussion 696 
The findings from this systematic review and meta-analysis suggest that collectively psychological 697 
interventions are effective for treating PTSD symptoms, symptoms of common mental health 698 
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problems, and improving sleep across all populations with a history of complex traumatic events. 699 
Evidence from non-randomised controlled trials generally supported this finding. These positive 700 
effects were especially pronounced for interventions with a trauma focus such as TF-CBT and EMDR 701 
and were observed over the longer term at 6-months and when compared with active controls. Non-702 
trauma focused interventions were not generally effective for PTSD symptoms, with only weak 703 
evidence in favour of IPT. There was less good evidence that psychological interventions were 704 
effective for managing the symptom cluster associated with disorders of self-regulation. We 705 
observed that TF-CBT was effective for managing negative self-concept and phase-based 706 
interventions were the leading candidate intervention to address inter-personal problems. No 707 
interventions were effective for managing emotional dysregulation. These findings were in the main 708 
endorsed by sub-group analyses across different populations exposed to complex traumatic events. 709 
In veteran and war-affected populations TF-CBT and EMDR were associated with the greatest 710 
reductions in PTSD symptoms and symptoms of depression and anxiety, but there was a diminution 711 
in effect sizes when compared with the results from the pooled analyses across all populations. 712 
Similarly TF-CBT and EMDR were effective for reducing PTSD symptoms in refugees and populations 713 
exposed to childhood sexual abuse, although the precision of the treatment estimates was more 714 
uncertain in the analysis of childhood sexual abuse trials. The largest effect sizes were observed in 715 
the domestic violence sub-group analysis which showed that TF-CBT was effective for managing 716 
PTSD symptoms, but this finding is based on limited evidence. The component network meta-717 
analysis showed that multi-component interventions that included at least cognitive restructuring 718 
and imaginal exposure were the most effective for managing PTSD symptoms. Furthermore, 719 
analyses indicated that psychological interventions were associated with larger effect sizes than 720 
pharmacological interventions for managing PTSD symptoms, symptoms of depression, and sleep at 721 
post-treatment. Antipsychotics were shown to be effective for PTSD symptoms but in the absence of 722 
safety data our review does not offer findings that might overturn existing clinical practice guidelines 723 
that recommend against the use of risperidone [144]. Prazosin was the only other pharmacological 724 
therapy that conferred modest benefits for PTSD symptoms and there is scope for revisiting 725 
recommendations against the use of this medication following further studies, especially in veterans. 726 
These findings partly concur with Merz et al who recently showed that psychotherapeutic 727 
treatments are superior to pharmacological treatments for adults with PTSD at last follow-up but not 728 
at end of treatment, reaffirming the view that pharmacological therapy should not be used as first-729 
line treatment for PTSD [145]. Our findings endorse this view and extend the relevance of 730 
international guideline recommendations that favour using TF-CBT and EMDR as first line treatment 731 
for PTSD symptoms to those with histories of complex trauma.  732 
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When broken down by trauma exposure we found a similar patterns of results observed in the 733 
pooled analyses across all populations. TF-CBT and EMDR were the most effective interventions for 734 
PTSD symptoms and common mental health problems for all sub-groups. Heterogeneity was 735 
significantly reduced in the meta-analyses of the primary outcome for psychological interventions 736 
across all sub-groups other than childhood sexual abuse. As previously shown, individual trauma-737 
focused treatments are efficacious for adult survivors of childhood sexual abuse with PTSD, albeit 738 
analyses have so far failed to unpack which elements of trauma-focused interventions are most 739 
effective [146]. Furthermore, effectiveness of trauma focused interventions can be reduced among 740 
the most complex cases of childhood sexual abuse with disturbances of self-organisation[147]. 741 
Similarly, previous reviews have shown that psychosocial interventions, and especially narrative 742 
exposure therapy, are effective for PTSD among refugees in both global and high-income settings 743 
[148, 149]. While our findings show that trauma focused interventions are also effective for mental 744 
comorbidities as well as PTSD among refugees there are still uncertainties about how to practically 745 
address mental ill health among the unprecedented surge in refugees, especially in low income 746 
settings [150]. 747 
Significantly, the size and durability of the treatment effects for PTSD and common mental health 748 
problems were diminished among veterans and war affected populations when compared with the 749 
results from the pooled analyses across all populations. Veterans have high rates of mental 750 
comorbidity and experience high levels of problems that can negatively impact successful 751 
engagement with psychological treatment, such as inter-personal problems and emotional 752 
dysregulation [151]. Phase-based interventions that seek to address disturbances of self-753 
organisation through skills based strategies in combination with strategies that address traumatic 754 
memories were among the most promising therapeutic approaches for emotional dysregulation and 755 
inter-personal problems in veteran and childhood sexual abuse populations. TF-CBT was the most 756 
effective approach for managing negative self-concept. Using combinations of trauma-focused 757 
therapies and skills based strategies in a flexible manner depending on symptom presentation is 758 
likely to be advantageous and removes the need for fixed approaches in cases of complex trauma 759 
[152]. 760 
This finding was partly endorsed by the component NMA which showed that multi-component 761 
interventions that included two or more intervention components are the most effective for 762 
managing PTSD symptoms in people with complex trauma. All effective multi-component 763 
interventions included imaginal exposure and cognitive restructuring, but this superordinate group 764 
of interventions also included phase-based interventions that combined skills based strategies with 765 
trauma-focused strategies. In this sense phase-based approaches can be realigned as multi-766 
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component treatments with phasing conceptualised as an intervention component rather than a 767 
separate intervention category. There is emerging evidence that multicomponent interventions that 768 
can be delivered in an integrated or sequenced way and target more than one outcome are 769 
efficacious for people with multiple and often competing health and behavioural problems [153], 770 
including those with complex trauma [154].  771 
Participants were less likely to drop out of psychological treatment than controls, even in studies 772 
judged to be at low risk of attrition bias, suggesting the difference in attrition between psychological 773 
intervention and controls is better explained by acceptability rather than attrition bias. Previously it 774 
has been shown that drop out among active and ex-service military personnel is higher for TF-CBT 775 
than present-centred therapy, especially where prolonged exposure is used [155]. This has relevance 776 
for understanding how acceptability of interventions and patient preference can inform effective 777 
delivery of treatments for people with complex trauma. Patient preference for psychological 778 
interventions is commonly reported [156], but it is imperative that systems are put in place to 779 
ensure people’s preferences are met to maximise likelihood of improving outcomes[157]. For 780 
example we showed that mindfulness was an effective treatment for depression among veterans 781 
but optimising delivery of such interventions as part of multicomponent packages needs to be 782 
cognisant of patient preferences about timing, setting and format [158]. There is scope to explore 783 
how established evidence-based patient centred frameworks such as the chronic care model can 784 
enhance and optimise the delivery of multicomponent care packages for people with complex 785 
trauma. While there is ample evidence that multifaceted and collaborative care packages are 786 
effective for managing depression and chronic disease in primary care [159, 160], there is only 787 
limited evidence that such patient-centred care approaches are similarly effective for people with 788 
PTSD and mental comorbidities [161]. 789 
Critical to any future research that might underpin patient-centred approaches is the need to 790 
capture outcomes that relate to broader notions about recovery that go beyond clinical recovery 791 
and include improvements in functioning and quality of life. We were only able to include data from 792 
six trials that measured quality of life but it is well established that people with PTSD have profound 793 
deficits in quality of life and physical limitations, more so than people with other anxiety disorders 794 
[162]. This is especially true among populations exposed to complex trauma such as veterans [163] 795 
and war-afflicted civilians [164] who often suffer impairments across multiple life domains, including 796 
social and occupational functioning. Assessment of PTSD-related quality of life should therefore be a 797 
priority in the context of trials to improve the mental health of people exposed to complex trauma.  798 
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Additionally, it is important to go beyond assessment of PTSD symptoms and consider broader 799 
psychosocial difficulties that stem from the experience of complex traumatic events. This is 800 
especially true among refuge populations whose emotional and behavioural problems are often 801 
linked to disruption in psychosocial systems that support mental health. Drawing on the Adaptation 802 
and Development After Persecution and Trauma (ADPAT) model critical psychosocial systems 803 
include safety and security, interpersonal bonds and networks, justice, identities and roles, and 804 
existential meaning [165]. Treatment strategies that embrace the need to counter disruption to 805 
these psychosocial domains might prove effective for promoting a more positive refugee experience. 806 
A recent trial has shown that in refugees from Myanmar a relatively brief 6-week course of 807 
integrative adapt therapy that is based on the ADAPT model led to improved adaptive capacity and 808 
resilience as well as greater reductions in PTSD symptoms and major depressive disorder compared 809 
with CBT [166]. While the effect size for PTSD symptoms was smaller in this trial than those reported 810 
in our meta-analyses of psychological interventions among refugees it might be that supporting 811 
adaptation to the refugee experience is as important as symptom control.  812 
 813 
Strengths and limitations 814 
This review attempted to capture the totality of all controlled evidence about the effectiveness of 815 
psychological and pharmacological treatments for people exposed to complex trauma. We included 816 
non-randomised controlled trials on the basis that these studies might include data about novel 817 
treatments delivered in pragmatic settings but the evidence from these trials was eclipsed by the 818 
evidence from randomised comparisons which offered the most robust assessments of treatment 819 
effectiveness. Our review has a number of strengths that further enhance the robustness of the 820 
findings. By taking an approach that favoured inclusion based on trauma exposure rather than 821 
diagnosis we were able to develop and operationalise broad inclusion criteria for the population of 822 
interest. In doing so, our search was not tied to a narrowly defined group of studies that exclusively 823 
evaluated interventions in populations with the as yet empirically untested diagnostic label of 824 
CPTSD, but rather captured a broader set of studies that addressed mental health problems in 825 
people exposed to complex traumatic events.  826 
Additional strengths of the review include the application of component NMA approaches to 827 
understanding treatment effectiveness and moderators of effectiveness. By searching extensively 828 
and adopting a broad approach to inclusion we were able to assemble a much larger data set than in 829 
previous reviews, enhancing our ability to quantify and explore heterogeneity and for the first time 830 
disentangle the effects of individual components of composite interventions. NMA offers additional 831 
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benefits over standard pairwise analyses in that the comparative efficacy of specific interventions 832 
can be estimated and ranked, even when two treatments have never been compared directly head‐833 
to‐head. Furthermore, since NMA can improve the precision of estimates by allowing integration of 834 
both direct and indirect treatment effect estimates, it is recommended over pairwise meta‐analyses 835 
by the World Health Organization as a basis for clinical guidelines [167].  836 
Despite using an extensive search strategy and applying broad inclusion criteria, our review has an 837 
underrepresentation of studies with a focus on complex trauma populations drawn from prison 838 
settings and survivors of torture and forced migrant labour, otherwise known as modern slavery. 839 
Future work should look to identify ways to ensure these populations are not overlooked. In 840 
addition, our search did not capture a critical mass of studies that included outcomes related to 841 
comorbid psychiatric states such as borderline personality disorder. This might have been offset had 842 
we adopted a more clinical and diagnostic approach to our inclusion criteria. While we did include 843 
populations with comorbidities, including psychosis and common mental health problems, we 844 
excluded those with dual diagnosis of complex trauma and substance and alcohol misuse on the 845 
grounds that these populations are likely to require care that is different from and more specialist 846 
than that typically provided in the context of PTSD. However, recent work has shown that treatment 847 
seeking veterans are more likely to report alcohol dependence and alcohol harm than active military 848 
personnel or the general population, highlighting the need in the future to assess the efficacy of 849 
mental health interventions for complex trauma populations with specific needs [168]. 850 
Benefits of treatment can diminish over the longer term, especially in populations exposed to 851 
complex trauma. However, most trials included in this review only reported post-treatment and 852 
short-term outcomes limiting evaluation of medium and longer-term outcomes. People with 853 
complex trauma experiences can benefit over the longer term from psychological therapies, but 854 
higher levels of mental health comorbidities are associated with poorer PTSD treatment response 855 
[169], suggesting that measurement of important secondary outcomes as well as PTSD symptoms is 856 
critical to understanding longer term impact of treatments.  857 
There was consistent evidence for the effectiveness of several psychological interventions, especially 858 
TF-CBT and EMDR, for improving PTSD, depression and anxiety symptoms. Effect estimates were 859 
lower for pharmacological interventions and lacked precision. However, we did not make any formal 860 
comparisons between psychological and pharmacological interventions either based on direct 861 
comparisons in trials or through network meta-analyses, and as such any informal comparisons are 862 
inherently uncertain. Furthermore it could be argued that comparisons about findings from RCTs of 863 
psychological versus pharmacological interventions might favour the former, where blinding may be 864 
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absent and a control for attention is missing. However there is compelling meta-epidemiological 865 
evidence that estimated treatment effects do not differ between trials with and without blinding of 866 
patients, healthcare providers, or outcome assessors[170]. 867 
While we were able to judge the acceptability of interventions there was insufficient data to assess 868 
harms related to either psychological or pharmacological interventions. Harms go beyond negative 869 
outcomes and refer to enduring negative effects that are directly caused by the therapy. The 870 
absence of harms data is more prevalent for trials of psychological than pharmacological trials [171] 871 
and this is an important omission given that at least 1 in 20 people report lasting bad effects from 872 
psychological treatment [172]. Going forwards there is a solid case to collect quantitative data about 873 
adverse events and clinically significant worsening of symptoms during and shortly after treatment, 874 
and also qualitative data about patients experience of harm [173].  875 
The NMA methods used were robust for most intervention components, but credible intervals were 876 
wide indicating very imprecise estimates. This reflects the exploratory nature of the analyses where 877 
we assessed a number of covariates. In addition, there were insufficient studies to tease apart the 878 
relative contribution of skills based components and these were pragmatically classed as 879 
multicomponent interventions. Finally, most studies included in the NMA had small sample sizes and 880 
high heterogeneity and were rated at either moderate or high risk of bias. Therefore, all estimates 881 
should be interpreted cautiously. 882 
 883 
Conclusion 884 
In conclusion existing evidence based psychological trauma-focused interventions are effective for 885 
managing PTSD symptoms and mental comorbidities in people with complex trauma histories. There 886 
was less good evidence that pharmacological interventions were effective for PTSD or mental 887 
comorbidities in the presence of complex trauma exposure. Trauma-focused interventions were 888 
generally less effective for managing disturbances of self-organisation as per ICD-11 definitions, with 889 
multi-component interventions showing some promise for managing these symptom clusters. 890 
Overall multicomponent interventions that included at least imaginal exposure and cognitive 891 
restructuring were the most effective for managing PTSD symptoms in complex trauma. There is a 892 
case for reconceptualising phasing as an element of multicomponent interventions and for the focus 893 
of the research and clinical community to now develop efficient and effective patient-centred 894 
strategies for delivery of multi-component treatments for complex trauma.  895 
  896 
30 
 
References 897 
1. Kessler RC, Aguilar-Gaxiola S, Alonso J, Benjet C, Bromet EJ, Cardoso G, et al. Trauma and 898 
PTSD in the WHO World Mental Health Surveys. Eur J Psychotraumatol. 2017;8(sup5):1353383. Epub 899 
2017/10/28. doi: 10.1080/20008198.2017.1353383. PubMed PMID: 29075426; PubMed Central 900 
PMCID: PMCPMC5632781. 901 
2. Stevelink SAM, Jones M, Hull L, Pernet D, MacCrimmon S, Goodwin L, et al. Mental health 902 
outcomes at the end of the British involvement in the Iraq and Afghanistan conflicts: a cohort study. 903 
Br J Psychiatry. 2018;213(6):690-7. Epub 2018/10/09. doi: 10.1192/bjp.2018.175. PubMed PMID: 904 
30295216; PubMed Central PMCID: PMCPMC6429255. 905 
3. Iversen AC, Fear NT, Simonoff E, Hull L, Horn O, Greenberg N, et al. Influence of childhood 906 
adversity on health among male UK military personnel. Br J Psychiatry. 2007;191:506-11. Epub 907 
2007/12/07. doi: 10.1192/bjp.bp.107.039818. PubMed PMID: 18055954. 908 
4. Steel Z, Chey T, Silove D, Marnane C, Bryant RA, van Ommeren M. Association of torture and 909 
other potentially traumatic events with mental health outcomes among populations exposed to 910 
mass conflict and displacement: A systematic review and meta-analysis. JAMA. 2009;302(5):537-49. 911 
doi: 10.1001/jama.2009.1132. 912 
5. UNHCR. Global Trends. Forced Displacement in 2018. Geneva: 2019. 913 
6. The management of PTSD in adults and children in primary and secondary care. National 914 
Clinical Practice Guideline Number 26, (2005). 915 
7. Bisson JI, Roberts NP, Andrew M, Cooper R, Lewis C. Psychological therapies for chronic 916 
post-traumatic stress disorder (PTSD) in adults. The Cochrane database of systematic reviews. 917 
2013;12:CD003388. doi: 10.1002/14651858.CD003388.pub4. PubMed PMID: 24338345. 918 
8. Ostacher MJ, Cifu AS. Management of Posttraumatic Stress Disorder. JAMA. 919 
2019;321(2):200-1. doi: 10.1001/jama.2018.19290. 920 
9. Stein DJ, Ipser JC, Seedat S, Sager C, Amos T. Pharmacotherapy for post traumatic stress 921 
disorder (PTSD). Cochrane Database of Systematic Reviews. 2006;(1). doi: 922 
10.1002/14651858.CD002795.pub2. PubMed PMID: CD002795. 923 
10. Hepgul N, King S, Amarasinghe M, Breen G, Grant N, Grey N, et al. Clinical characteristics of 924 
patients assessed within an Improving Access to Psychological Therapies (IAPT) service: results from 925 
a naturalistic cohort study (Predicting Outcome Following Psychological Therapy; PROMPT). BMC 926 
Psychiatry. 2016;16(1):52. doi: 10.1186/s12888-016-0736-6. PubMed PMID: 26920578; PubMed 927 
Central PMCID: PMCPMC4769576. 928 
11. Briere J, Kaltman S, Green BL. Accumulated childhood trauma and symptom complexity. J 929 
Trauma Stress. 2008;21(2):223-6. Epub 2008/04/12. doi: 10.1002/jts.20317. PubMed PMID: 930 
18404627. 931 
12. Cloitre M, Stolbach BC, Herman JL, van der Kolk B, Pynoos R, Wang J, et al. A developmental 932 
approach to complex PTSD: childhood and adult cumulative trauma as predictors of symptom 933 
complexity. J Trauma Stress. 2009;22(5):399-408. doi: 10.1002/jts.20444. PubMed PMID: 19795402. 934 
13. Goddard E, Wingrove J, Moran P. The impact of comorbid personality difficulties on 935 
response to IAPT treatment for depression and anxiety. Behav Res Ther. 2015;73:1-7. doi: 936 
10.1016/j.brat.2015.07.006. PubMed PMID: 26226089. 937 
14. Karatzias T, Shevlin M, Fyvie C, Hyland P, Efthymiadou E, Wilson D, et al. Evidence of distinct 938 
profiles of Posttraumatic Stress Disorder (PTSD) and Complex Posttraumatic Stress Disorder (CPTSD) 939 
based on the new ICD-11 Trauma Questionnaire (ICD-TQ). J Affect Disord. 2017;207:181-7. Epub 940 
2016/10/11. doi: 10.1016/j.jad.2016.09.032. PubMed PMID: 27723542. 941 
15. Karatzias T, Murphy P, Cloitre M, Bisson J, Roberts N, Shevlin M, et al. Psychological 942 
interventions for ICD-11 complex PTSD symptoms: systematic review and meta-analysis. 943 
Psychological Medicine. 2019;49(11):1761-75. Epub 2019/03/12. doi: 10.1017/S0033291719000436. 944 
16. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA 945 
Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of 946 
31 
 
Health Care Interventions: Checklist and Explanations. Annals of Internal Medicine. 947 
2015;162(11):777-84. doi: 10.7326/m14-2385. 948 
17. Herman JL. Complex PTSD: A syndrome in survivors of prolonged and repeated trauma. 949 
Journal of Traumatic Stress. 1992;5(3):377-91. doi: 10.1002/jts.2490050305. 950 
18. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane 951 
Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 952 
10.1136/bmj.d5928. 953 
19. Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG, Turner EH, et al. Comparative 954 
efficacy and acceptability of first-generation and second-generation antidepressants in the acute 955 
treatment of major depression: protocol for a network meta-analysis. BMJ Open. 956 
2016;6(7):e010919. doi: 10.1136/bmjopen-2015-010919. 957 
20. NICE. Methods for the Development of NICE Public Health Guidance. 3rd edn. Appendix F: 958 
quality appraisal checklist – quantitative intervention studies. London: 2012. 959 
21. Jackson R, Ameratunga S, Broad J, Connor J, Lethaby A, Robb G, et al. The GATE frame: 960 
critical appraisal with pictures. Evid Based Nurs. 2006;9(3):68-71. Epub 2006/07/26. doi: 961 
10.1136/ebn.9.3.68. PubMed PMID: 16862733. 962 
22. StataCorp. Stata Statistical Software: Release 15. College Station: StataCorp LP; 2017. 963 
23. Lipsey MW, Wilson D. Practical Meta-Analysis. Thousand Oaks: Sage Publictions Inc; 2001. 964 
24. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 965 
5.1.0: Cochrane Collaboration; 2011. 966 
25. Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison meta-967 
analysis of complex interventions: psychological interventions in coronary heart disease. Am J 968 
Epidemiol. 2009;169(9):1158-65. doi: 10.1093/aje/kwp014. PubMed PMID: 19258485. 969 
26. Freeman SC, Scott NW, Powell R, Johnston M, Sutton AJ, Cooper NJ. Component network 970 
meta-analysis identifies the most effective components of psychological preparation for adults 971 
undergoing surgery under general anesthesia. Journal of Clinical Epidemiology. 2018;98:105-16. doi: 972 
https://doi.org/10.1016/j.jclinepi.2018.02.012. 973 
27. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence Synthesis for Decision Making 2:A 974 
Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized 975 
Controlled Trials. Medical Decision Making. 2013;33(5):607-17. doi: 10.1177/0272989x12458724. 976 
PubMed PMID: 23104435. 977 
28. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model 978 
complexity and fit. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 979 
2002;64(4):583-639. doi: 10.1111/1467-9868.00353. 980 
29. Adenauer H, Catani C, Gola H, Keil J, Ruf M, Schauer M, et al. Narrative exposure therapy for 981 
PTSD increases top-down processing of aversive stimuli--evidence from a randomized controlled 982 
treatment trial. BMC Neurosci. 2011;12:127. doi: https://dx.doi.org/10.1186/1471-2202-12-127 983 
PubMed PMID: 22182346. 984 
30. Azad Marzabadi E, Hashemi Zadeh SM. The effectiveness of mindfulness training in 985 
improving the quality of life of the war victims with post traumatic stress disorder (PTSD). Iran. 986 
2014;9(4):228-36. PubMed PMID: 25792991. 987 
31. Bahadir-Yilmaz E, Oz F. The Effectiveness of Empowerment Program on Increasing Self-988 
Esteem, Learned Resourcefulness, and Coping Ways in Women Exposed to Domestic Violence. Issues 989 
in Mental Health Nursing. 2018;39(2):135-41. doi: 10.1080/01612840.2017.1368750. PubMed PMID: 990 
WOS:000424943000005. 991 
32. Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS. Adjunctive risperidone in the treatment of 992 
chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005;57(5):474-9. doi: 993 
10.1016/j.biopsych.2004.11.039. PubMed PMID: 15737661. 994 
33. Beidel DC, Frueh BC, Uhde TW, Wong N, Mentrikoski JM. Multicomponent behavioral 995 
treatment for chronic combat-related posttraumatic stress disorder: a randomized controlled trial. 996 
Journal of Anxiety Disorders. 2011;25(2):224-31. doi: 997 
32 
 
https://dx.doi.org/10.1016/j.janxdis.2010.09.006 PubMed PMID: 20951543; PubMed Central PMCID: 998 
PMCNIHMS238163. 999 
34. Bremner JD, Mishra S, Campanella C, Shah M, Kasher N, Evans S, et al. A pilot study of the 1000 
effects of mindfulness-based stress reduction on post-traumatic stress disorder symptoms and brain 1001 
response to traumatic reminders of combat in Operation Enduring Freedom/Operation Iraqi 1002 
Freedom combat veterans with post-traumatic stress disorder. Frontiers in Psychiatry Vol 8 2017, 1003 
ArtID 157. 2017;8. doi: 10.3389/fpsyt.2017.00157. PubMed PMID: 2017-38563-001. 1004 
35. Celik C, Ozdemir B, Ozmenler KN, Yelboga Z, Balikci A, Oznur T, et al. Efficacy of Paroxetine 1005 
and Amitriptyline in Posttraumatic Stress Disorder: An Open-label Comparative Study. Klinik 1006 
Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 2011;21(3):179-85. doi: 1007 
10.5455/bcp.20110627111141. 1008 
36. Chard KM. An evaluation of cognitive processing therapy for the treatment of posttraumatic 1009 
stress disorder related to childhood sexual abuse. J Consult Clin Psychol. 2005;73(5):965-71. doi: 1010 
10.1037/0022-006X.73.5.965. PubMed PMID: 16287396. 1011 
37. Chung MY, Min KH, Jun YJ, Kim SS, Kim WC, Jun EM. Efficacy and tolerability of mirtazapine 1012 
and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. 1013 
Hum. 2004;19(7):489-94. doi: 10.1002/hup.615. PubMed PMID: 15378676. 1014 
38. Classen C, Koopman C, Nevillmanning K, Spiegel D. A Preliminary Report Comparing Trauma-1015 
Focused and Present-Focused Group Therapy Against a Wait-Listed Condition Among Childhood 1016 
Sexual Abuse Survivors with PTSD. Journal of Aggression, Maltreatment & Trauma. 2001;4(2):265-88. 1017 
doi: 10.1300/J146v04n02_12. 1018 
39. Cook JM, Harb GC, Gehrman PR, Cary MS, Gamble GM, Forbes D, et al. Imagery rehearsal for 1019 
posttraumatic nightmares: a randomized controlled trial. Journal of traumatic stress. 1020 
2010;23(5):553-63. doi: 10.1002/jts.20569  1021 
40. Davis LL, Jewell ME, Ambrose S, Farley J, English B, Bartolucci A, et al. A Placebo-Controlled 1022 
Study of Nefazodone for the Treatment of Chronic Posttraumatic Stress Disorder: A Preliminary 1023 
Study. Journal of Clinical Psychopharmacology. 2004;24(3). doi: 1024 
10.1097/01.jcp.0000125685.82219.1a. 1025 
41. Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F. Divalproex in the 1026 
treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a 1027 
veteran population. J Clin Psychopharmacol. 2008;28(1):84-8. doi: 1028 
https://dx.doi.org/10.1097/JCP.0b013e318160f83b. PubMed PMID: 18204347. 1029 
42. Devilly GJ, Spence SH, Rapee RM. Statistical and reliable change with eye movement 1030 
desensitization and reprocessing: Treating trauma within a veteran population. Behavior Therapy. 1031 
1998;29(3):435-55. doi: https://doi.org/10.1016/S0005-7894(98)80042-7. 1032 
43. Foa EB, McLean CP, Zang Y, Rosenfield D, Yadin E, Yarvis JS, et al. Effect of Prolonged 1033 
Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD 1034 
Symptom Severity in Military Personnel: A Randomized Clinical Trial. JAMA. 2018;319(4):354-64. doi: 1035 
https://dx.doi.org/10.1001/jama.2017.21242. PubMed PMID: 29362795. 1036 
44. Ford JD, Grasso DJ, Greene CA, Slivinsky M, DeViva JC. Randomized clinical trial pilot study of 1037 
prolonged exposure versus present centred affect regulation therapy for PTSD and anger problems 1038 
with male military combat veterans. Clin. 2018;25(5):641-9. doi: 1039 
https://dx.doi.org/10.1002/cpp.2194. PubMed PMID: 29687524. 1040 
45. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind 1041 
comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans 1042 
Affairs setting. Journal of Clinical Psychiatry. 2007;68(5):711-20. doi: 10.4088/jcp.v68n0508. PubMed 1043 
PMID: 17503980. 1044 
46. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW. Adjunctive 1045 
risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on 1046 
comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003;18(1):1-8. doi: 1047 
10.1097/01.yic.0000050744.67514.6d. PubMed PMID: 12490768. 1048 
33 
 
47. Himmerich H, Willmund GD, Zimmermann P, Wolf JE, Buhler AH, Kirkby KC, et al. Serum 1049 
concentrations of TNF-alphas soluble receptors during psychotherapy in German soldiers suffering 1050 
from combat-related PTSD. Psychiatria Danubina. 2016;28(3):293-8. doi: 10.4103/0366-6999.178039 1051 
PubMed PMID: 612523930. 1052 
48. Jensen JA. An investigation of eye movement desensitization and reprocessing (EMD/R) as a 1053 
treatment for posttraumatic stress disorder (PTSD) symptoms of Vietnam combat veterans. Behavior 1054 
Therapy. 1994;25(2):311-25. doi: 10.1016/S0005-7894(05)80290-4. PubMed PMID: 1994-42215-001. 1055 
49. Jung K, Steil R. A randomized controlled trial on cognitive restructuring and imagery 1056 
modification to reduce the feeling of being contaminated in adult survivors of childhood sexual 1057 
abuse suffering from posttraumatic stress disorder. Psychother Psychosom. 2013;82(4):213-20. doi: 1058 
https://dx.doi.org/10.1159/000348450 PubMed PMID: 23712073. 1059 
50. Keane TM, Fairbank JA, Caddell JM, Zimering RT. Implosive (flooding) therapy reduces 1060 
symptoms of PTSD in Vietnam combat veterans. Behavior Therapy. 1989;20(2):245-60. doi: 1061 
https://doi.org/10.1016/S0005-7894(89)80072-3. 1062 
51. Kearney DJ, McDermott K, Malte C, Martinez M, Simpson TL. Effects of participation in a 1063 
mindfulness program for veterans with posttraumatic stress disorder: a randomized controlled pilot 1064 
study. J Clin Psychol. 2013;69(1):14-27. doi: 10.1002/jclp.21911. PubMed PMID: 22930491. 1065 
52. King AP, Erickson TM, Giardino ND, Favorite T, Rauch SA, Robinson E, et al. A pilot study of 1066 
group mindfulness-based cognitive therapy (MBCT) for combat veterans with posttraumatic stress 1067 
disorder (PTSD). Depress Anxiety. 2013;30(7):638-45. doi: https://dx.doi.org/10.1002/da.22104 1068 
PubMed PMID: 23596092; PubMed Central PMCID: PMCNIHMS671148. 1069 
53. Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, et al. Adjunctive 1070 
risperidone treatment for antidepressant-resistant symptoms of chronic military service-related 1071 
PTSD: a randomized trial. JAMA. 2011;306(5):493-502. doi: 1072 
https://dx.doi.org/10.1001/jama.2011.1080 PubMed PMID: 21813427. 1073 
54. Lande RG, Williams LB, Francis JL, Gragnani C, Morin ML. Efficacy of biofeedback for post-1074 
traumatic stress disorder. Complement Ther Med. 2010;18(6):256-9. doi: 1075 
https://dx.doi.org/10.1016/j.ctim.2010.08.004 PubMed PMID: 21130362. 1076 
55. Lau M, Kristensen E. Outcome of systemic and analytic group psychotherapy for adult 1077 
women with history of intrafamilial childhood sexual abuse: a randomized controlled study. Acta 1078 
Psychiatrica Scandinavica. 2007;116(2):96-104. doi: 10.1111/j.1600-0447.2006.00977.x. PubMed 1079 
PMID: WOS:000248087900003. 1080 
56. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of 1081 
augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin 1082 
Psychopharmacol. 2007;27(6):677-81. doi: https://dx.doi.org/10.1097/jcp.0b013e31815a43ee. 1083 
PubMed PMID: 18004136. 1084 
57. Lundqvist G, Svedin CG, Hansson K, Broman I. Group therapy for women sexually abused as 1085 
children: mental health before and after group therapy. J Interpers Violence. 2006;21(12):1665-77. 1086 
doi: 10.1177/0886260506294986. PubMed PMID: 17065660. 1087 
58. Margolies SO, Rybarczyk B, Lynch J, Vrana S. Efficacy of a cognitive-behavioral treatment for 1088 
insomnia among Afghanistan and Iraq (OEF/ OIF) veterans with PTSD. Sleep. 2011;34:A253-A4. doi: 1089 
0.1002/jclp.21970. PubMed PMID: 71510995. 1090 
59. McDonagh A, Friedman M, McHugo G, Ford J, Sengupta A, Mueser K, et al. Randomized trial 1091 
of cognitive-behavioral therapy for chronic posttraumatic stress disorder in adult female survivors of 1092 
childhood sexual abuse. J Consult Clin Psychol. 2005;73(3):515-24. doi: 10.1037/0022-006X.73.3.515. 1093 
PubMed PMID: 15982149. 1094 
60. Monnelly EP, Ciraulo DA, Knapp C, Keane T. Low-Dose Risperidone as Adjunctive Therapy for 1095 
Irritable Aggression in Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology. 1096 
2003;23(2). doi: 10.1097/00004714-200304000-00012. 1097 
61. Moradi AR, Moshirpanahi S, Parhon H, Mirzaei J, Dalgleish T, Jobson L. A pilot randomized 1098 
controlled trial investigating the efficacy of MEmory Specificity Training in improving symptoms of 1099 
34 
 
posttraumatic stress disorder. Behaviour Research & Therapy. 2014;56:68-74. doi: 1100 
https://dx.doi.org/10.1016/j.brat.2014.03.002 PubMed PMID: 24705337. 1101 
62. Nakamura Y, Lipschitz DL, Donaldson GW, Kida Y, Williams SL, Landward R, et al. 1102 
Investigating Clinical Benefits of a Novel Sleep-Focused Mind-Body Program on Gulf War Illness 1103 
Symptoms: A Randomized Controlled Trial. Psychosom Med. 2017;79(6):706-18. doi: 1104 
https://dx.doi.org/10.1097/PSY.0000000000000469. PubMed PMID: 28406803. 1105 
63. Naylor JC, Dolber TR, Strauss JL, Kilts JD, Strauman TJ, Bradford DW, et al. A pilot randomized 1106 
controlled trial with paroxetine for subthreshold PTSD in Operation Enduring Freedom/Operation 1107 
Iraqi Freedom era veterans. Psychiatry Research. 2013;206(2-3):318-20. doi: 1108 
10.1016/j.psychres.2012.11.008. PubMed PMID: 2013-00092-001. 1109 
64. Otto MW, Hinton D, Korbly NB, Chea A, Ba P, Gershuny BS, et al. Treatment of 1110 
pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study 1111 
of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther. 1112 
2003;41(11):1271-6. doi: 10.1016/s0005-7967(03)00032-9. PubMed PMID: 14527527. 1113 
65. Paunovic N, Ost LG. Cognitive-behavior therapy vs exposure therapy in the treatment of 1114 
PTSD in refugees. Behav Res Ther. 2001;39(10):1183-97. doi: 10.1016/S0005-7967(00)00093-0. 1115 
PubMed PMID: 11579988. 1116 
66. Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine versus fluphenazine in an open trial in 1117 
patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology. 1118 
2004;175(4):451-6. doi: 10.1007/s00213-004-1849-z. PubMed PMID: 2004-19344-008. 1119 
67. Polusny MA, Erbes CR, Thuras P, Moran A, Lamberty GJ, Collins RC, et al. Mindfulness-based 1120 
stress reduction for posttraumatic stress disorder among veterans: a randomized clinical trial. JAMA. 1121 
2015;314(5):456-65. doi: https://dx.doi.org/10.1001/jama.2015.8361 PubMed PMID: 26241597. 1122 
68. Possemato K, Bergen-Cico D, Treatman S, Allen C, Wade M, Pigeon W. A randomized clinical 1123 
trial of primary care brief mindfulness training for veterans with PTSD. J Clin Psychol. 1124 
2016;72(3):179-93. doi: https://dx.doi.org/10.1002/jclp.22241 PubMed PMID: 26613203. 1125 
69. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, et al. A parallel group 1126 
placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat 1127 
veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928-34. doi: 1128 
https://dx.doi.org/10.1016/j.biopsych.2006.06.032. PubMed PMID: 17069768. 1129 
70. Raskind MA, Peterson K, Williams T, Hoff DJ, Peskind ER. A trial of prazosin for combat 1130 
trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J 1131 
Psychiatry. 2013;170(9):1003-10. doi: 10.1176/appi.ajp.2013.12081133. 1132 
71. Rauch SA, Kim H, Powell C, Tuerk PW, Simon NM, Acierno R, et al. Efficacy of prolonged 1133 
exposure therapy, sertraline hydrochloride, and their combination among combat veterans with 1134 
posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry. 2019;76(2):117-25. doi: 1135 
http://dx.doi.org/10.1001/jamapsychiatry.2018.3412. PubMed PMID: 2019-07144-001. 1136 
72. Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C. A preliminary study of risperidone 1137 
in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin 1138 
Psychiatry. 2004;65(12):1601-6. PubMed PMID: 15641864. 1139 
73. Rogers S, Silver SM, Goss J, Obenchain J, Willis A, Whitney RL. A Single Session, Group Study 1140 
of Exposure and Eye Movement Desensitization and Reprocessing in Treating Posttraumatic Stress 1141 
Disorder Among Vietnam War Veterans: Preliminary Data. J Anxiety Disord. 1999;13(1):119-30. doi: 1142 
https://doi.org/10.1016/S0887-6185(98)00043-7. 1143 
74. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related 1144 
PTSD: A double-blind, placebo-controlled study. The American Journal of Psychiatry. 1145 
2002;159(10):1777-9. doi: 10.1176/appi.ajp.159.10.1777. PubMed PMID: 2002-04602-025. 1146 
75. Stenmark H, Catani C, Neuner F, Elbert T, Holen A. Treating PTSD in refugees and asylum 1147 
seekers within the general health care system. A randomized controlled multicenter study. Behav 1148 
Res Ther. 2013;51(10):641-7. doi: https://dx.doi.org/10.1016/j.brat.2013.07.002 PubMed PMID: 1149 
23916633. 1150 
35 
 
76. Teng EJ, Bailey SD, Chaison AD, Petersen NJ, Hamilton JD, Dunn NJ. Treating comorbid panic 1151 
disorder in veterans with posttraumatic stress disorder. J Consult Clin Psychol. 2008;76(4):704-10. 1152 
doi: https://dx.doi.org/10.1037/0022-006X.76.4.710 PubMed PMID: 18665698. 1153 
77. Ulmer CS, Edinger JD, Calhoun PS. A multi-component cognitive-behavioral intervention for 1154 
sleep disturbance in veterans with PTSD: a pilot study. J Clin Sleep Med. 2011;7(1):57-68. PubMed 1155 
PMID: 21344046. 1156 
78. Van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, et al. Fluoxetine in 1157 
posttraumatic stress disorder. J Clin Psychiatry. 1994;55(12):517-22. PubMed PMID: 25026437. 1158 
79. Bichescu D, Neuner F, Schauer M, Elbert T. Narrative exposure therapy for political 1159 
imprisonment-related chronic posttraumatic stress disorder and depression. Behaviour Research & 1160 
Therapy. 2007;45(9):2212-20. doi: 10.1016/j.brat.2006.12.006. PubMed PMID: 17288990. 1161 
80. Bonilla-Escobar FJ, Fandino-Losada A, Martinez-Buitrago DM, Santaella-Tenorio J, Tobon-1162 
Garcia D, Munoz-Morales EJ, et al. A randomized controlled trial of a transdiagnostic cognitive-1163 
behavioral intervention for Afro-descendants' survivors of systemic violence in Colombia. PLoS ONE. 1164 
2018;13(12):e0208483. doi: https://dx.doi.org/10.1371/journal.pone.0208483. PubMed PMID: 1165 
30532155. 1166 
81. Buhmann CB, Nordentoft M, Ekstroem M, Carlsson J, Mortensen EL. The effect of flexible 1167 
cognitive-behavioural therapy and medical treatment, including antidepressants on post-traumatic 1168 
stress disorder and depression in traumatised refugees: pragmatic randomised controlled clinical 1169 
trial. British Journal of Psychiatry. 2016;208(3):252-9. doi: 1170 
https://dx.doi.org/10.1192/bjp.bp.114.150961 PubMed PMID: 26541687. 1171 
82. Carlson JG, Chemtob CM, Rusnak K, Hedlund NL, Muraoka MY. Eye movement 1172 
desensitization and reprocessing (EMDR) treatment for combat-related posttraumatic stress 1173 
disorder. Japanese Journal of Biofeedback Research. 1997;24:50-64. doi: 10.1023/A:1024448814268. 1174 
PubMed PMID: 1999-13197-003. 1175 
83. Carlsson J, Sonne C, Vindbjerg E, Mortensen EL. Stress management versus cognitive 1176 
restructuring in trauma-affected refugees-A pragmatic randomised study. Psychiatry Research. 1177 
2018;266:116-23. doi: https://dx.doi.org/10.1016/j.psychres.2018.05.015. PubMed PMID: 1178 
29859498. 1179 
84. Cloitre M, Stovall-McClough KC, Nooner K, Zorbas P, Cherry S, Jackson CL, et al. Treatment 1180 
for PTSD related to childhood abuse: a randomized controlled trial. Am J Psychiatry. 1181 
2010;167(8):915-24. doi: https://dx.doi.org/10.1176/appi.ajp.2010.09081247 PubMed PMID: 1182 
20595411. 1183 
85. Feske U. Treating low-income and minority women with posttraumatic stress disorder: a 1184 
pilot study comparing prolonged exposure and treatment as usual conducted by community 1185 
therapists. J Interpers Violence. 2008;23(8):1027-40. doi: 1186 
https://dx.doi.org/10.1177/0886260507313967. PubMed PMID: 18292398. 1187 
86. Hermenau K, Hecker T, Schaal S, Maedl A, Elbert T. Addressing post-traumatic stress and 1188 
aggression by means of narrative exposure: A randomized controlled trial with ex-combatants in the 1189 
eastern DRC. Journal of Aggression, Maltreatment and Trauma. 2013;22(8):916-34. doi: 1190 
http://dx.doi.org/10.1080/10926771.2013.824057 PubMed PMID: 369892869. 1191 
87. Hijazi AM, Lumley MA, Ziadni MS, Haddad L, Rapport LJ, Arnetz BB. Brief narrative exposure 1192 
therapy for posttraumatic stress in Iraqi refugees: a preliminary randomized clinical trial. Journal of 1193 
Traumatic Stress. 2014;27(3):314-22. doi: https://dx.doi.org/10.1002/jts.21922 PubMed PMID: 1194 
24866253; PubMed Central PMCID: PMCNIHMS595425. 1195 
88. Hinton DE, Chhean D, Pich V, Safren SA, Hofmann SG, Pollack MH. A randomized controlled 1196 
trial of cognitive-behavior therapy for Cambodian refugees with treatment-resistant PTSD and panic 1197 
attacks: a cross-over design. Journal of Traumatic Stress. 2005;18(6):617-29. doi: 10.1002/jts.20070. 1198 
PubMed PMID: 16382423. 1199 
89. Hinton DE, Pham T, Tran M, Safren SA, Otto MW, Pollack MH. CBT for Vietnamese refugees 1200 
with treatment-resistant PTSD and panic attacks: a pilot study. Journal of Traumatic Stress. 1201 
36 
 
2004;17(5):429-33. doi: 10.1023/B:JOTS.0000048956.03529.fa. PubMed PMID: 15633922; PubMed 1202 
Central PMCID: PMCNIHMS144174. 1203 
90. Kosten TR, Krystal JH, Giller EL, Frank J, Dan E. Alexithymia as a predictor of treatment 1204 
response in post-traumatic stress disorder. Journal of Traumatic Stress. 1992;5(4):563-73. doi: 1205 
10.1016/j.biopsych.2013.05.017. PubMed PMID: 1993-18480-001. 1206 
91. Krupnick JL, Green BL, Stockton P, Miranda J, Krause E, Mete M. Group interpersonal 1207 
psychotherapy for low-income women with posttraumatic stress disorder. Psychother. 1208 
2008;18(5):497-507. doi: https://dx.doi.org/10.1080/10503300802183678. PubMed PMID: 1209 
18816001. 1210 
92. Kubany ES, Hill EE, Owens JA. Cognitive trauma therapy for battered women with PTSD: 1211 
preliminary findings. Journal of Traumatic Stress. 2003;16(1):81-91. doi: 10.1023/A:1022019629803. 1212 
PubMed PMID: 12602656. 1213 
93. Kubany ES, Hill EE, Owens JA, Iannce-Spencer C, McCaig MA, Tremayne KJ, et al. Cognitive 1214 
trauma therapy for battered women with PTSD (CTT-BW). Journal of Consulting & Clinical 1215 
Psychology. 2004;72(1):3-18. doi: https://dx.doi.org/10.1037/0022-006X.72.1.3 PubMed PMID: 1216 
14756610. 1217 
94. Meffert SM, Abdo AO, Alla OAA, Elmakki YOM, Omer AA, Yousif S, et al. A pilot randomized 1218 
controlled trial of interpersonal psychotherapy for Sudanese refugees in Cairo, Egypt. Psychological 1219 
Trauma: Theory, Research, Practice, and Policy. 2014;6(3):240-9. doi: 10.1037/a0023540. 1220 
95. Morgan T, Cummings AL. Change experienced during group therapy by female survivors of 1221 
childhood sexual abuse. Journal of Consulting and Clinical Psychology. 1999;67(1):28-36. doi: 1222 
10.1037/0022-006X.67.1.28. 1223 
96. Salo J, Punamaki R-L, Qouta S, El Sarraj E. Individual and group treatment and self and other 1224 
representations predicting posttraumatic recovery among former political prisoners. Traumatology. 1225 
2008;14(2):45-61. doi: 10.1177/1534765608319079. PubMed PMID: 2009-10421-005. 1226 
97. Sikkema KJ, Hansen NB, Kochman A, Tarakeshwar N, Neufeld S, Meade CS, et al. Outcomes 1227 
from a group intervention for coping with HIV/AIDS and childhood sexual abuse: reductions in 1228 
traumatic stress. Aids Behav. 2007;11(1):49-60. doi: https://dx.doi.org/10.1007/s10461-006-9149-8. 1229 
PubMed PMID: 16858634. 1230 
98. Sikkema KJ, Ranby KW, Meade CS, Hansen NB, Wilson PA, Kochman A. Reductions in 1231 
traumatic stress following a coping intervention were mediated by decreases in avoidant coping for 1232 
people living with HIV/AIDS and childhood sexual abuse. J Consult Clin Psychol. 2013;81(2):274-83. 1233 
doi: https://dx.doi.org/10.1037/a0030144 PubMed PMID: 23025248; PubMed Central PMCID: 1234 
PMCNIHMS433358. 1235 
99. Sonne C, Carlsson J, Bech P, Elklit A, Mortensen EL. Treatment of trauma-affected refugees 1236 
with venlafaxine versus sertraline combined with psychotherapy-A randomised study. BMC 1237 
Psychiatry Vol 16 2016, ArtID 383. 2016;16. doi: 10.1186/s12888-016-1081-5. PubMed PMID: 2016-1238 
54614-001. 1239 
100. Thorp SR, Glassman LH, Wells SY, Walter KH, Gebhardt H, Twamley E, et al. A randomized 1240 
controlled trial of prolonged exposure therapy versus relaxation training for older veterans with 1241 
military-related PTSD. Journal of Anxiety Disorders. 2019;64:45-54. doi: 1242 
http://dx.doi.org/10.1016/j.janxdis.2019.02.003. PubMed PMID: 2019-27063-007. 1243 
101. Weiss WM, Murray LK, Zangana GA, Mahmooth Z, Kaysen D, Dorsey S, et al. Community-1244 
based mental health treatments for survivors of torture and militant attacks in Southern Iraq: a 1245 
randomized control trial. BMC Psychiatry. 2015;15:249. doi: https://dx.doi.org/10.1186/s12888-015-1246 
0622-7 PubMed PMID: 26467303. 1247 
102. Yeomans PD, Forman EM, Herbert JD, Yuen EK. A randomized trial of a reconciliation 1248 
workshop with and without PTSD psychoeducation in Burundian sample. Journal of Traumatic Stress. 1249 
2010;23(3):305-12. doi: http://dx.doi.org/10.1002/jts.20531  1250 
37 
 
103. Gamito P, Oliveira J, Rosa P, Morais D, Duarte N, OLiverira S, et al. PTSD Elderly War 1251 
Veterans: A Clinical Controlled Pilot Study. Cyberpsychology, Behavior, and Social Networking. 1252 
2010;13(1):43-8. doi: 10.1089/cyber.2009.0237. PubMed PMID: 20528292. 1253 
104. Germain A, Richardson R, Moul DE, Mammen O, Haas G, Forman SD, et al. Placebo-1254 
controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US 1255 
Military Veterans. J Psychosom Res. 2012;72(2):89-96. doi: 1256 
https://dx.doi.org/10.1016/j.jpsychores.2011.11.010 PubMed PMID: 22281448; PubMed Central 1257 
PMCID: PMCNIHMS342239. 1258 
105. Katz LS, Douglas S, Zaleski K, Williams J, Huffman C, Cojucar G. Comparing holographic 1259 
reprocessing and prolonged exposure for women veterans with sexual trauma: A pilot randomized 1260 
trial. Journal of Contemporary Psychotherapy. 2014;44(1):9-19. doi: 1261 
http://dx.doi.org/10.1007/s10879-013-9248-6 PubMed PMID: 52756441. 1262 
106. McLay RN, Wood DP, Webb-Murphy JA, Spira JL, Wiederhold MD, Pyne JM, et al. A 1263 
randomized, controlled trial of virtual reality-graded exposure therapy for post-traumatic stress 1264 
disorder in active duty service members with combat-related post-traumatic stress disorder. 1265 
Cyberpsychol Behav Soc Netw. 2011;14(4):223-9. doi: https://dx.doi.org/10.1089/cyber.2011.0003 1266 
PubMed PMID: 21332375. 1267 
107. Reger GM, Koenen-Woods P, Zetocha K, Smolenski DJ, Holloway KM, Rothbaum BO, et al. 1268 
Randomized controlled trial of prolonged exposure using imaginal exposure vs. virtual reality 1269 
exposure in active duty soldiers with deployment-related posttraumatic stress disorder (PTSD). 1270 
Journal of Consulting and Clinical Psychology. 2016;84(11):946-59. doi: 1271 
http://dx.doi.org/10.1037/ccp0000134 PubMed PMID: 612057864. 1272 
108. Resick PA, Wachen JS, Mintz J, Young-McCaughan S, Roache JD, Borah AM, et al. A 1273 
randomized clinical trial of group cognitive processing therapy compared with group present-1274 
centered therapy for PTSD among active duty military personnel. J Consult Clin Psychol. 1275 
2015;83(6):1058-68. doi: https://dx.doi.org/10.1037/ccp0000016 PubMed PMID: 25939018. 1276 
109. Miyahira SD, Folen RA, Hoffman HG, Garcia-Palacios A, Spira JL, Kawasaki M. The 1277 
effectiveness of VR exposure therapy for PTSD in returning warfighters. Annual Review of 1278 
CyberTherapy and Telemedicine. 2012;10:128-32. doi: 10.3233/978-1-61499-121-2-128. 1279 
110. Acarturk C, Konuk E, Cetinkaya M, Senay I, Sijbrandij M, Cuijpers P, et al. EMDR for Syrian 1280 
refugees with posttraumatic stress disorder symptoms: results of a pilot randomized controlled trial. 1281 
European Journal of Psychotraumatology. 2015;6:27414. doi: 1282 
https://dx.doi.org/10.3402/ejpt.v6.27414 PubMed PMID: 25989952. 1283 
111. Acarturk C, Konuk E, Cetinkaya M, Senay I, Sijbrandij M, Gulen B, et al. The efficacy of eye 1284 
movement desensitization and reprocessing for post-traumatic stress disorder and depression 1285 
among Syrian refugees: results of a randomized controlled trial. Psychological Medicine. 1286 
2016;46(12):2583-93. doi: https://dx.doi.org/10.1017/S0033291716001070 PubMed PMID: 1287 
27353367. 1288 
112. Neuner F, Schauer M, Klaschik C, Karunakara U, Elbert T. A comparison of narrative exposure 1289 
therapy, supportive counseling, and psychoeducation for treating posttraumatic stress disorder in an 1290 
African refugee settlement. J Consult Clin Psychol. 2004;72(4):579-87. doi: 10.1037/0022-1291 
006X.72.4.579. PubMed PMID: 15301642. 1292 
113. Neuner F, Onyut PL, Ertl V, Odenwald M, Schauer E, Elbert T. Treatment of posttraumatic 1293 
stress disorder by trained lay counselors in an African refugee settlement: a randomized controlled 1294 
trial. J Consult Clin Psychol. 2008;76(4):686-94. doi: https://dx.doi.org/10.1037/0022-006X.76.4.686 1295 
PubMed PMID: 18665696. 1296 
114. Yurtsever A, Konuk E, Akyuz T, Zat Z, Tukel F, Cetinkaya M, et al. An Eye Movement 1297 
Desensitization and Reprocessing (EMDR) Group Intervention for Syrian Refugees With Post-1298 
traumatic Stress Symptoms: Results of a Randomized Controlled Trial. Front Psychol. 2018;9:493. 1299 
doi: https://dx.doi.org/10.3389/fpsyg.2018.00493. PubMed PMID: 29946275. 1300 
38 
 
115. Engel CC, Litz B, Magruder KM, Harper E, Gore K, Stein N, et al. Delivery of self training and 1301 
education for stressful situations (DESTRESS-PC): a randomized trial of nurse assisted online self-1302 
management for PTSD in primary care. Gen Hosp Psychiatry. 2015;37(4):323-8. doi: 1303 
https://dx.doi.org/10.1016/j.genhosppsych.2015.04.007 PubMed PMID: 25929985; PubMed Central 1304 
PMCID: PMCNIHMS680713. 1305 
116. Franklin CL, Cuccurullo LA, Walton JL, Arseneau JR, Petersen NJ. Face to face but not in the 1306 
same place: A pilot study of prolonged exposure therapy. Journal of Trauma and Dissociation. 1307 
2017;18(1):116-30. doi: http://dx.doi.org/10.1080/15299732.2016.1205704 PubMed PMID: 1308 
611575198. 1309 
117. Knaevelsrud C, Böttche M, Pietrzak RH, Freyberger HJ, Kuwert P. Efficacy and Feasibility of a 1310 
Therapist-Guided Internet-Based Intervention for Older Persons with Childhood Traumatization: A 1311 
Randomized Controlled Trial. American Journal of Geriatric Psychiatry. 2017;25(8):878-88. doi: 1312 
10.1016/j.jagp.2017.02.024. PubMed PMID: 124186984. 1313 
118. Knaevelsrud C, Brand J, Lange A, Ruwaard J, Wagner B. Web-based psychotherapy for 1314 
posttraumatic stress disorder in war-traumatized Arab patients: randomized controlled trial. J Med 1315 
Internet Res. 2015;17(3):e71. doi: https://dx.doi.org/10.2196/jmir.3582 PubMed PMID: 25799024. 1316 
119. Ter Heide FJ, Mooren TM, Kleijn W, de Jongh A, Kleber RJ. EMDR versus stabilisation in 1317 
traumatised asylum seekers and refugees: results of a pilot study. European Journal of 1318 
Psychotraumatology. 2011;2. doi: https://dx.doi.org/10.3402/ejpt.v2i0.5881 PubMed PMID: 1319 
22893808. 1320 
120. Ter Heide FJ, Mooren TM, van de Schoot R, de Jongh A, Kleber RJ. Eye movement 1321 
desensitisation and reprocessing therapy v. stabilisation as usual for refugees: randomised 1322 
controlled trial. British Journal of Psychiatry. 2016;209(4):311-8. doi: 1323 
https://dx.doi.org/10.1192/bjp.bp.115.167775 PubMed PMID: 26892849. 1324 
121. Wahbeh H, Goodrich E, Goy E, Oken BS. Mechanistic pathways of mindfulness meditation in 1325 
combat veterans with posttraumatic stress disorder. J Clin Psychol. 2016;72(4):365-83. doi: 1326 
https://dx.doi.org/10.1002/jclp.22255 PubMed PMID: 26797725; PubMed Central PMCID: 1327 
PMCNIHMS744049 [Available on 04/01/17]. 1328 
122. Wang SJ, Bytyci A, Izeti S, Kallaba M, Rushiti F, Montgomery E, et al. A novel bio-psycho-1329 
social approach for rehabilitation of traumatized victims of torture and war in the post-conflict 1330 
context: a pilot randomized controlled trial in Kosovo. Confl Health. 2016;10:34. doi: 1331 
https://dx.doi.org/10.1186/s13031-016-0100-y PubMed PMID: 28191034. 1332 
123. Niles BL, Klunk-Gillis J, Ryngala DJ, Silberbogen AK, Paysnick A, EJ. W. Comparing mindfulness 1333 
and psychoeducation treatments for combat-related PTSD using a telehealth approach. 1334 
Psychological Trauma: Theory, Research, Practice, and Policy. 2012;4:538-47. doi: 1335 
10.1037/a0026161. 1336 
124. Panahi Y, Moghaddam BR, Sahebkar A, Nazari MA, Beiraghdar F, Karami G, et al. A 1337 
randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in 1338 
Iranian veterans with post-traumatic stress disorder. Psychological Medicine. 2011;41(10):2159-66. 1339 
doi: https://dx.doi.org/10.1017/S0033291711000201 PubMed PMID: 21349225. 1340 
125. Bass J, Murray SM, Mohammed TA, Bunn M, Gorman W, Ahmed AM, et al. A Randomized 1341 
Controlled Trial of a Trauma-Informed Support, Skills, and Psychoeducation Intervention for 1342 
Survivors of Torture and Related Trauma in Kurdistan, Northern Iraq. Global health, science and 1343 
practice. 2016;4(3):452-66. doi: http://dx.doi.org/10.9745/GHSP-D-16-00017. PubMed PMID: 1344 
619970238. 1345 
126. Bolton P, Bass JK, Zangana GA, Kamal T, Murray SM, Kaysen D, et al. A randomized 1346 
controlled trial of mental health interventions for survivors of systematic violence in Kurdistan, 1347 
Northern Iraq. BMC Psychiatry. 2014;14:360. doi: https://dx.doi.org/10.1186/s12888-014-0360-2 1348 
PubMed PMID: 25551436. 1349 
127. Ardani AR, Hosseini G, Bordbar MR, Talaei A, Toroghi HM. Effect of rivastigmine 1350 
augmentation in treatment of male patients with combat-related chronic posttraumatic stress 1351 
39 
 
disorder a randomized controlled trial. Journal of Clinical Psychopharmacology (USA). 2017;37(1):54-1352 
60. doi: 10.1097/JCP.0000000000000624. 1353 
128. Becker ME, Hertzberg MA, Moore SD, Dennis MF, Beckham JC. A placebo-controlled trial of 1354 
bupropion SR in the treatment of chronic posttraumatic stress disorder. Journal of Clinical 1355 
Psychopharmacology (USA). 2007;27(2):193-7. doi: 10.1097/JCP.0b013e318032eaed. 1356 
129. Edmond T, Rubin A, Wambach KG. The effectiveness of EMDR with adult female survivors of 1357 
childhood sexual abuse. Social Work Research. 1999;23(2):103-16. doi: 10.1093/swr/23.2.103. 1358 
130. Franciskovic T, Sukovic Z, Janovic S, Stevanovic A, Nemcic-Moro I, Roncevic-Grzeta I, et al. 1359 
Tianeptine in the combined treatment of combat related poasttraumatic stress disorder. Psychiatria 1360 
Danubina. 2011;23(3):257-63. PubMed PMID: 2011-23671-010. 1361 
131. Galano MM, Grogan-Kaylor AC, Stein SF, Clark HM, Graham-Bermann SA. Posttraumatic 1362 
stress disorder in Latina women: Examining the efficacy of the Moms' Empowerment Program. 1363 
Psychol Trauma. 2017;9(3):344-51. doi: https://dx.doi.org/10.1037/tra0000218. PubMed PMID: 1364 
27869463. 1365 
132. Kruse J, Joksimovic L, Cavka M, Woller W, Schmitz N. Effects of trauma-focused 1366 
psychotherapy upon war refugees. Journal of Traumatic Stress. 2009;22(6):585-92. doi: 1367 
https://dx.doi.org/10.1002/jts.20477 PubMed PMID: 19960519. 1368 
133. Levi O, Bar-Haim Y, Kreiss Y, Fruchter E. Cognitive-behavioural therapy and psychodynamic 1369 
psychotherapy in the treatment of combat-related post-traumatic stress disorder: a comparative 1370 
effectiveness study. Clinical Psychology & Psychotherapy. 2016;23(4):298-307. doi: 1371 
10.1002/cpp.1969 PubMed PMID: 117169055. 1372 
134. Narimani M, Sadeghieh Ahari S, Rajabi S. Comparison of efficacy of eye movement 1373 
desensitization and reprocessing and cognitive behavioral therapy therapeutic methods for reducing 1374 
anxiety and depression of Iranian combatant afflicted by post traumatic stress disorder. Journal of 1375 
Applied Sciences. 2008;8(10):1932-7. doi: http://dx.doi.org/10.3923/jas.2008.1932.1937  1376 
135. Owens GP, Pike JL, Chard KM. Treatment effects of cognitive processing therapy on cognitive 1377 
distortions of female child sexual abuse survivors. Behavior Therapy. 2001;32(3):413-24. PubMed 1378 
PMID: 2002-12369-001. 1379 
136. Ready DJ, Gerardi RJ, Backscheider AG, Mascaro N, Rothbaum BO. Comparing virtual reality 1380 
exposure therapy to present-centered therapy with 11 U.S. Vietnam veterans with PTSD. 1381 
Cyberpsychol Behav Soc Netw. 2010;13(1):49-54. doi: 10.1089/cyber.2009.0239. PubMed PMID: 1382 
20528293. 1383 
137. Reed GL, Enright RD. The effects of forgiveness therapy on depression, anxiety, and 1384 
posttraumatic stress for women after spousal emotional abuse. J Consult Clin Psychol. 1385 
2006;74(5):920-9. doi: https://dx.doi.org/10.1037/0022-006X.74.5.920. PubMed PMID: 17032096. 1386 
138. Saxe BJ, Johnson SM. An empirical investigation of group treatment for a clinical population 1387 
of adult female incest survivors. Journal of Child Sexual Abuse. 1999;8(1):67-88. doi: 1388 
https://doi.org/10.1300/J070v08n01_05. PubMed PMID: 107099962. 1389 
139. Shapiro E, Laub B, Rosenblat O. Early EMDR intervention following intense rocket attacks on 1390 
a town: A randomised clinical trial. Clinical Neuropsychiatry: Journal of Treatment Evaluation. 1391 
2018;15(3):194-205. PubMed PMID: 2018-27261-003. 1392 
140. Smajkic A, Weine S, Djuric-Bijedic Z, Boskailo E, Lewis J, Pavkovic I. Sertraline, paroxetine, 1393 
and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of 1394 
Traumatic Stress. 2001;14(3):445-52. doi: https://dx.doi.org/10.1023/A:1011177420069. PubMed 1395 
PMID: 11534876. 1396 
141. Spidel A, Lecomte T, Kealy D, Daigneault I. Acceptance and commitment therapy for 1397 
psychosis and trauma: Improvement in psychiatric symptoms, emotion regulation, and treatment 1398 
compliance following a brief group intervention. Psychology and Psychotherapy-Theory Research 1399 
and Practice. 2018;91(2):248-61. doi: 10.1111/papt.12159. PubMed PMID: WOS:000434168200007. 1400 
40 
 
142. Zlotnick C, Shea TM, Rosen K, Simpson E, Mulrenin K, Begin A, et al. An affect-management 1401 
group for women with posttraumatic stress disorder and histories of childhood sexual abuse. Journal 1402 
of Traumatic Stress. 1997;10(3):425-36. doi: 10.1023/a:1024841321156. PubMed PMID: 9246650. 1403 
143. Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane RM, et al. Double-blind placebo-1404 
controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of 1405 
Clinical Psychopharmacology. 2002;22(2):190-5. doi: 10.1097/00004714-200204000-00013. PubMed 1406 
PMID: 11910265. 1407 
144. VA/DoD. Clinical Pratice Guideline for the Management of Posttrauatic Stress Disorder and 1408 
Acute Stress Disorder. 2017. 1409 
145. Merz J, Schwarzer G, Gerger H. Comparative Efficacy and Acceptability of Pharmacological, 1410 
Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A 1411 
Network Meta-analysis. JAMA Psychiatry. 2019. Epub 2019/06/13. doi: 1412 
10.1001/jamapsychiatry.2019.0951. PubMed PMID: 31188399; PubMed Central PMCID: 1413 
PMCPMC6563588. 1414 
146. Ehring T, Welboren R, Morina N, Wicherts JM, Freitag J, Emmelkamp PM. Meta-analysis of 1415 
psychological treatments for posttraumatic stress disorder in adult survivors of childhood abuse. Clin 1416 
Psychol Rev. 2014;34(8):645-57. Epub 2014/12/03. doi: 10.1016/j.cpr.2014.10.004. PubMed PMID: 1417 
25455628. 1418 
147. Karatzias T, Murphy P, Cloitre M, Bisson J, Roberts N, Shevlin M, et al. Psychological 1419 
interventions for ICD-11 complex PTSD symptoms: systematic review and meta-analysis. Psychol 1420 
Med. 2019;49(11):1761-75. Epub 2019/03/13. doi: 10.1017/S0033291719000436. PubMed PMID: 1421 
30857567. 1422 
148. Turrini G, Purgato M, Acarturk C, Anttila M, Au T, Ballette F, et al. Efficacy and acceptability 1423 
of psychosocial interventions in asylum seekers and refugees: systematic review and meta-analysis. 1424 
Epidemiol Psychiatr Sci. 2019;28(4):376-88. Epub 2019/02/12. doi: 10.1017/S2045796019000027. 1425 
PubMed PMID: 30739625; PubMed Central PMCID: PMCPMC6669989. 1426 
149. Nose M, Ballette F, Bighelli I, Turrini G, Purgato M, Tol W, et al. Psychosocial interventions 1427 
for post-traumatic stress disorder in refugees and asylum seekers resettled in high-income countries: 1428 
Systematic review and meta-analysis. PLoS ONE. 2017;12(2):e0171030. Epub 2017/02/06. doi: 1429 
10.1371/journal.pone.0171030. PubMed PMID: 28151992; PubMed Central PMCID: 1430 
PMCPMC5289495. 1431 
150. Silove D, Ventevogel P, Rees S. The contemporary refugee crisis: an overview of mental 1432 
health challenges. World Psychiatry. 2017;16(2):130-9. Epub 2017/05/13. doi: 10.1002/wps.20438. 1433 
PubMed PMID: 28498581; PubMed Central PMCID: PMCPMC5428192. 1434 
151. Landes SJ, Garovoy ND, Burkman KM. Treating complex trauma among veterans: three 1435 
stage-based treatment models. J Clin Psychol. 2013;69(5):523-33. Epub 2013/03/27. doi: 1436 
10.1002/jclp.21988. PubMed PMID: 23529776. 1437 
152. Cloitre M. The "one size fits all" approach to trauma treatment: should we be satisfied? Eur J 1438 
Psychotraumatol. 2015;6:27344. Epub 2015/05/23. doi: 10.3402/ejpt.v6.27344. PubMed PMID: 1439 
25994021; PubMed Central PMCID: PMCPMC4439409. 1440 
153. Weisz JR, Chorpita BF, Palinkas LA, Schoenwald SK, Miranda J, Bearman SK, et al. Testing 1441 
standard and modular designs for psychotherapy treating depression, anxiety, and conduct 1442 
problems in youth: a randomized effectiveness trial. Arch Gen Psychiatry. 2012;69(3):274-82. Epub 1443 
2011/11/09. doi: 10.1001/archgenpsychiatry.2011.147. PubMed PMID: 22065252. 1444 
154. Sabri B, Gielen A. Integrated Multicomponent Interventions for Safety and Health Risks 1445 
Among Black Female Survivors of Violence: A Systematic Review. Trauma Violence Abuse. 1446 
2017:1524838017730647. Epub 2018/01/16. doi: 10.1177/1524838017730647. PubMed PMID: 1447 
29334001; PubMed Central PMCID: PMCPMC5771976. 1448 
155. Kitchiner NJ, Lewis C, Roberts NP, Bisson JI. Active duty and ex-serving military personnel 1449 
with post-traumatic stress disorder treated with psychological therapies: systematic review and 1450 
41 
 
meta-analysis. European journal of psychotraumatology. 2019;10(1):1684226-. doi: 1451 
10.1080/20008198.2019.1684226. PubMed PMID: 31762951. 1452 
156. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for 1453 
psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin 1454 
Psychiatry. 2013;74(6):595-602. Epub 2013/07/12. doi: 10.4088/JCP.12r07757. PubMed PMID: 1455 
23842011. 1456 
157. Williams R, Farquharson L, Palmer L, Bassett P, Clarke J, Clark DM, et al. Patient preference 1457 
in psychological treatment and associations with self-reported outcome: national cross-sectional 1458 
survey in England and Wales. BMC Psychiatry. 2016;16:4. Epub 2016/01/16. doi: 10.1186/s12888-1459 
015-0702-8. PubMed PMID: 26768890; PubMed Central PMCID: PMCPMC4714467. 1460 
158. Martinez ME, Kearney DJ, Simpson T, Felleman BI, Bernardi N, Sayre G. Challenges to 1461 
Enrollment and Participation in Mindfulness-Based Stress Reduction Among Veterans: A Qualitative 1462 
Study. J Altern Complement Med. 2015;21(7):409-21. Epub 2015/07/03. doi: 1463 
10.1089/acm.2014.0324. PubMed PMID: 26133205. 1464 
159. Katon WJ, Lin EHB, Von Korff M, Ciechanowski P, Ludman EJ, Young B, et al. Collaborative 1465 
Care for Patients with Depression and Chronic Illnesses. New England Journal of Medicine. 1466 
2010;363(27):2611-20. doi: doi:10.1056/NEJMoa1003955. PubMed PMID: 21190455. 1467 
160. Coventry P, Lovell K, Dickens C, Bower P, Chew-Graham C, McElvenny D, et al. Integrated 1468 
primary care for patients with mental and physical multimorbidity: cluster randomised controlled 1469 
trial of collaborative care for patients with depression comorbid with diabetes or cardiovascular 1470 
disease. BMJ. 2015;350:h638. doi: 10.1136/bmj.h638. PubMed PMID: 25687344. 1471 
161. Engel CC, Jaycox LH, Freed MC, Bray RM, Brambilla D, Zatzick D, et al. Centrally Assisted 1472 
Collaborative Telecare for Posttraumatic Stress Disorder and Depression Among Military Personnel 1473 
Attending Primary Care: A Randomized Clinical Trial. JAMA Intern Med. 2016;176(7):948-56. Epub 1474 
2016/06/14. doi: 10.1001/jamainternmed.2016.2402. PubMed PMID: 27294447. 1475 
162. Mark Hyman Rapaport, M.D. ,, Cathryn Clary, M.D. ,, Rana Fayyad, Ph.D. , and, Jean Endicott, 1476 
Ph.D. Quality-of-Life Impairment in Depressive and Anxiety Disorders. Am J Psychiatry. 1477 
2005;162(6):1171-8. doi: 10.1176/appi.ajp.162.6.1171. PubMed PMID: 15930066. 1478 
163. Barrett DH, Doebbeling CC, Schwartz DA, Voelker MD, Falter KH, Woolson RF, et al. 1479 
Posttraumatic Stress Disorder and Self-Reported Physical Health Status Among U.S. Military 1480 
Personnel Serving During the Gulf War Period: A Population-Based Study. Psychosomatics. 1481 
2002;43(3):195-205. doi: https://doi.org/10.1176/appi.psy.43.3.195. 1482 
164. Giacco D, Matanov A, Priebe S. Symptoms and Subjective Quality of Life in Post-Traumatic 1483 
Stress Disorder: A Longitudinal Study. PLoS ONE. 2013;8(4):e60991. doi: 1484 
10.1371/journal.pone.0060991. 1485 
165. Silove D. The ADAPT model: A conceptual framework for mental health and psychosocial 1486 
programming in post conflict settings. Intervention: International Journal of Mental Health, 1487 
Psychosocial Work & Counselling in Areas of Armed Conflict. 2013;11(3):237-48. doi: 1488 
10.1097/WTF.0000000000000005. 1489 
166. Tay AK, Mung HK, Miah MAA, Balasundaram S, Ventevogel P, Badrudduza M, et al. An 1490 
Integrative Adapt Therapy for common mental health symptoms and adaptive stress amongst 1491 
Rohingya, Chin, and Kachin refugees living in Malaysia: A randomized controlled trial. PLOS 1492 
Medicine. 2020;17(3):e1003073. doi: 10.1371/journal.pmed.1003073. 1493 
167. Kanters S, Ford N, Druyts E, Thorlund K, Mills EJ, N B. Use of network meta-analysis in clinical 1494 
guidelines. Bulletin of the World Health Organisation. 2016;94:782-4. 1495 
168. Murphy D, Turgoose D. Exploring patterns of alcohol misuse in treatment-seeking UK 1496 
veterans: A cross-sectional study. Addictive Behaviors. 2019;92:14-9. doi: 1497 
https://doi.org/10.1016/j.addbeh.2018.11.044. 1498 
169. Murphy D, Spencer-Harper L, Carson C, Palmer E, Hill K, Sorfleet N, et al. Long-term 1499 
responses to treatment in UK veterans with military-related PTSD: an observational study. BMJ 1500 
Open. 2016;6(9):e011667. doi: 10.1136/bmjopen-2016-011667. 1501 
42 
 
170. Moustgaard H, Clayton GL, Jones HE, Boutron I, Jørgensen L, Laursen DRT, et al. Impact of 1502 
blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. 1503 
BMJ. 2020;368:l6802. doi: 10.1136/bmj.l6802. 1504 
171. Vaughan B, Goldstein MH, Alikakos M, Cohen LJ, Serby MJ. Frequency of reporting of 1505 
adverse events in randomized controlled trials of psychotherapy vs. psychopharmacotherapy. 1506 
Comprehensive Psychiatry. 2014;55(4):849-55. doi: 1507 
https://doi.org/10.1016/j.comppsych.2014.01.001. 1508 
172. Crawford MJ, Thana L, Farquharson L, Palmer L, Hancock E, Bassett P, et al. Patient 1509 
experience of negative effects of psychological treatment: results of a national survey. British Journal 1510 
of Psychiatry. 2016;208(3):260-5. Epub 2018/01/02. doi: 10.1192/bjp.bp.114.162628. 1511 
173. Parry GD, Crawford MJ, Duggan C. Iatrogenic harm from psychological therapies – time to 1512 
move on. British Journal of Psychiatry. 2016;208(3):210-2. Epub 2018/01/02. doi: 1513 
10.1192/bjp.bp.115.163618. 1514 
 1515 
  1516 
43 
 
S1 Text 1517 
PRISMA NMA Checklist of Items to Include When Reporting A Systematic Review Involving a 1518 
Network Meta-analysis 1519 
 1520 
S2 Text 1521 
Sample search strategy in Ovid MEDLINE 1522 
 1523 
S1 Table  1524 
Characteristics of included studies 1525 
ACT  – acceptance and commitment therapy, CBT – cognitive behavioural therapy, DBT  – dialectical 1526 
behavioural therapy, EMDR – eye movement desensitization and reprocessing, IPT – interpersonal 1527 
therapy, NTCBT  – non-trauma focused CBT, MBCT – mindfulness based cognitive therapy, MBSR – 1528 
mindfulness based stress reduction, PE  – prolonged exposure, NR  – not reported, RCT – 1529 
randomised controlled trial, SSRI  – selective serotonin reuptake inhibitor, STAIR – skills training in 1530 
affective and interpersonal regulation, TAU – treatment as usual, TFCBT – trauma-focused CBT. 1531 
 1532 
S2 Table  1533 
Risk of bias assessments for randomised controlled trials 1534 
 1535 
S3 Table  1536 
Risk of bias assessments for non-randomised controlled trial 1537 
- significant sources of bias; + potential sources of bias; ++ minimal sources of bias; NA = not 1538 
applicable; NR = not reported. 1539 
 1540 
S4 Table  1541 
Effect sizes (standardised mean difference) for psychological and pharmacological 1542 
interventions versus control in all populations 1543 
BDI: Beck depression inventory, CAPS: clinician administered PTSD scale, CBT – cognitive behavioural 1544 
therapy, EMDR – eye movement desensitisation and reprocessing therapy, IPT – interpersonal 1545 
therapy, PANSS – positive and negative syndrome scale, PTSD – post-traumatic stress disorder, SSRI 1546 
– selective serotonin reuptake inhibitor, TF-CBT – trauma-focused cognitive behavioural therapy. 1547 
 1548 
S5 Table  1549 
Effect sizes (standardised mean difference) for psychological interventions versus control for 1550 
complex trauma exposure sub-groups 1551 
44 
 
EMDR – eye movement desensitisation and reprocessing therapy, TF-CBT – trauma focused cognitive 1552 
behavioural therapy, PTSD – post-traumatic stress disorder 1553 
 1554 
S6 Table  1555 
Mean difference for outcomes by intervention component 1556 
 1557 
